A comprehensive review of intravitreal immunosuppressants and biologics used in ophthalmology

Nasiq Hasan, Rohan Chawla, Nawazish Shaikh, Sindhuja Kandasamy, Shorya Vardhan Azad and M. Dheepak Sundar

Abstract: Systemic immunosuppressants and biologicals have been a valuable tool in the treatment of inflammatory diseases and malignancies. The safety profile of these drugs has been debatable, especially in localized systems, such as the eye. This has led to the search for fairly local approaches, such as intravitreal, subconjunctival, and topical route of administration. Immunosuppressants have been used as a second-line drug in patients intolerable to corticosteroids or those who develop multiple recurrences on weaning corticosteroids. Similarly, biologicals have also been used as the next line of therapy, when adequate control of inflammation could not be attained or immunosuppressants were contraindicated to patients. Intravitreal immunosuppressants, such as methotrexate and sirolimus, have been extensively studied in noninfectious posterior uveitis, whereas limited studies have established the efficacy of intravitreal biologicals, such as infliximab and adalimumab. Most of these drugs have shown good safety profile and tolerability in animal studies alone and have not been studied further in human subjects. However, most of the studies in literature are single-case reports or case series which limits the level of evidence. In this comprehensive review, we discuss the mechanism of action, pharmacodynamics, pharmacokinetics, indications, efficacy, and side effects of different intravitreal immunosuppressants and biologicals that have been studied in literature.

Keywords: adalimumab, cyclosporine, etanercept, golimumab, infliximab, intravitreal, methotrexate, natalizumab, rituximab, sirolimus, tacrolimus

Received: 29 April 2021; revised manuscript accepted: 11 April 2022.

Introduction
In the last two decades, a large number of immunosuppressants and biologics have been studied for various indications, such as intraocular lymphoma, uveitis, age-related macular degeneration, diabetic macular edema, and proliferative vitreoretinopathy (PVR). Quite a lot of pre-clinical animal studies have provided initial data on the pharmacokinetics and safety of these molecules. Following which many of these molecules have also been tested in clinical trials. In this review, we aim to summarize the observations of these studies.

Method of literature search
Literature search for this review was done extensively using PubMed and Cochrane database. The following keywords and their iterations were used for the search; ‘intravitreal immunosuppressant’ and ‘intravitreal biologicals’. Out of the 9584 related articles, we excluded intravitreal steroids and systemic drugs and found studies and case reports on four immunosuppressants and six biologicals, namely ‘intravitreal methotrexate’, ‘intravitreal sirolimus’, ‘intravitreal tacrolimus’, ‘intravitreal cyclosporine’, ‘intravitreal infliximab’, ‘intravitreal adalimumab’, ‘intravitreal etanercept’, ‘intravitreal golimumab’, ‘intravitreal natalizumab’, and ‘intravitreal rituximab’. Out of 524 articles, we excluded duplications, studies with only systemic use of the drug, and narrative reviews. Articles were carefully read, and those that included animal studies, pharmacokinetic and pharmacodynamics (PKPD)
studies, human studies, and case reports and adverse effects were considered for the review.

**Immunosuppressants**
The following immunosuppressants have been used intravitreally either in human patients/subjects or in animal models (Table 1):

- Methotrexate.
- Sirolimus.
- Cyclosporine.
- Tacrolimus.

**Methotrexate**
Methotrexate (MTX) works by inhibiting the dihydrofolate reductase (DHFR) enzyme which is needed for folate synthesis, thereby inhibiting DNA synthesis and cell proliferation. MTX polyglutamates inhibit aminoimidazole-4-carboxamide ribonucleotide (AICAR) transformylase (ATIC) which leads to the release of adenosine into the extracellular matrix. This further leads to the inhibition of leukocytes, chemotaxis, and secretion of TNF-alpha, interleukin (IL)-8, and IL 6 by monocytes. MTX was first approved by United States Food and Drug Administration (US FDA) in 1953 as a subcutaneous injection for patients with rheumatoid arthritis, polyarticular juvenile idiopathic arthritis (JIA), and recalcitrant psoriasis. However, it has started being widely used as an oral and an intravenous agent as chemotherapy for malignant tumors, immunosuppressant for autoimmune diseases, and as an abortifacient to terminate pregnancies. In ophthalmology, its intravitreal use was initially restricted to the cases of intraocular lymphoma; however, currently investigators have explored its utility in many other ocular pathologies as well.

**Pharmacokinetics.** In a study in rabbits in which intravitreal injection of 800 μg/0.1 mL of MTX was administered, the volume of distribution was 1.33 mL and the drug remained over the effective dose for almost 81 h with a half-life of 5.9 h. In another study, therapeutic levels of MTX were observed in the vitreous at 48–72 h of intravitreal injection of 400 μg/0.1 mL of the drug.

**Animal studies.** Short-term and long-term ultrastructural changes were studied in rabbit models after injecting high-dose (800 μg/0.1 mL) MTX intravitreally at serial intervals. Early changes included retinal edema, vacuolization, and disintegration of retinal mitochondrial cells, and long-term effects included cellular disorganization in different retinal layers. Eman et al. showed a significant reduction in a-wave and b-wave on electroretinogram (ERG), raised relative caspase-3 activity and typical ladder pattern of internucleosomal fragmentation on gel electrophoresis (characteristic of apoptosis) on injecting 800 μg/0.1 mL MTX into the vitreous cavity. Single intravitreal injection of 400 and 800 μg of MTX did not show significant anti-inflammatory effects in experimentally induced uveitis in rabbits. However, Deng et al. found intravitreal MTX to be better than dexamethasone in

---

**Table 1. Properties of intravitreal immunosuppressants.**

| Drug       | Mechanism of action | First FDA approval | Route of administration       | Systemic dose | Intravitreal dose | Vitreous half-life (days) |
|------------|---------------------|--------------------|--------------------------------|---------------|------------------|--------------------------|
| Methotrexate | DHFR enzyme inhibitor | 1953 for RA and JIA | Intravenous, intramuscular, subcutaneous, oral, and intrathecal | Dose varies widely | 400 μg/0.1 mL | 5.9 h                   |
| Sirolimus   | mTOR inhibition     | 2015 for LAM       | Oral                           | Dose varies widely | 352 μg          | 8–9 days                |
| Cyclosporine| Calcineurin inhibitor | 1983 for organ transplantation | Oral                          | Dose varies widely | –                | NK                      |
| Tacrolimus  | Calcineurin inhibitor | 1994 for organ transplantation | Oral                          | Dose varies widely | –                | NK                      |

DHFR, dihydrofolate reductase; FDA, Food and Drug Administration; JIA, juvenile idiopathic arthritis; LAM, lymphangioleiomyomatosis; mTOR, mammalian target of rapamycin; NK, not known; RA, rheumatoid arthritis.
reducing inflammation in experimentally induced bacterial endophthalmitis with *Staphylococcus epidermidis* in rabbits. Drug-loaded hydrogels in a portable iontophoretic device, chitosan, and polyactic acid-based MTX intravitreal microneedle implants, along with lipophilic surface modification using Poly(lactic-co-glycolic acid) (PLGA) and biodegradable microneedle implants were studied and all of them showed increased duration and safe release of the drug when injected into the vitreous cavity.

**Vitreoretinal lymphoma.** Intravitreal MTX has been the drug of choice in vitreoretinal lymphomas (especially unilateral cases) and is usually combined with systemic chemotherapy and radiotherapy in bilateral cases and those associated with central nervous system (primary central nervous system lymphoma (PCNSL)). There is a single case report describing complete remission with bilateral intravitreal MTX alone in bilateral primary intraocular lymphoma (PIOL) without CNS involvement. The patient did not show any signs of recurrence or CNS disease until 15 months follow-up. Intravitreal MTX does not protect against CNS involvement and systemic therapy is required to treat concurrent CNS lymphoma. The preferred dose of the intravitreal regimen, described by Fishburne et al., is 400 μg/0.1 mL. Twice weekly injections are recommended in the first 4 weeks, followed by once weekly for 8 weeks, and once monthly for the next 9 months. A single dose of intravitreal MTX (400 μg/0.1 mL) was effective for 5 days. The safety and efficacy of this regimen was evaluated by Smith et al., and they found that all patients were clinically cleared of the malignant cells within a maximum of 12 injections. Another study by Ma et al. showed complete remission of PIOL in cases treated with a combination of intravitreal MTX and intravenous high-dose MTX. Many other studies have shown similar remission rates with the same regimen. Intravitreal MTX has also been combined with intravitreal rituximab to reduce the toxicity of MTX. Systemic high-dose MTX following intravitreal regimen showed a better duration of CNS lymphoma-free survival than those treated with intravitreal regimen alone. A study also showed that the combination of treatment modalities (intravitreal MTX injections, MTX-based systemic induction chemotherapy and consolidation high-dose cytarabine and reduced-dose whole brain radiation therapy) for PIOL showed reduction in CNS relapse and increase in progression-free survival and overall survival without change in cognitive dysfunction. Patients who underwent combined systemic and intraocular chemotherapy had better CNS relapse-free survival, failure-free survival, and overall survival rates according to a single-center experience of 28 years which studied primary vitreoretinal lymphoma (PVRL), concurrent VRL and CNSL, and secondary VRL. Patients with PVRL had significantly better overall survival compared to the concurrent disease. A single case report showed complete regression of PIOL lesion with repeated cycles of intravitreal MTX (three doses at Days 1, 5, and 8) followed by subtenon dexamethasone (on Day 9) at 4- to 6-week intervals. This regimen can serve as a palliative therapy for certain patients. Intravitreal MTX has been effective as a rescue treatment in relapse of PIOL following systemic chemotherapy and radiotherapy. A case of massive subretinal lymphoma was treated with monthly injection of MTX and rituximab for 3 months and showed massive reduction in the size of the lesion and significant improvement of vision without any CNS or ocular relapse. Another case of diffuse large B-cell lymphoma (DLBCL) with bilateral iris involvement also showed significant reduction of tumor size with six doses of intravitreal MTX.

**Mantle cell lymphoma.** Combination of chemotherapy, systemic ibrutinib, intravitreal MTX, and rituximab has shown marked improvement in a patient with anterior segment metastasis of mantle cell lymphoma. A diagnosed case of mantle cell lymphoma on systemic chemotherapy (CHOP regimen) was presented with bilateral ciliary body mass and anterior uveitis with hypopyon in the left eye. The patient underwent 40 Gy external beam irradiation in 20 fractions over a period of 1 month followed by multiple doses of intravitreal MTX (400 μg/0.1 mL) in the left eye over 12 months. Complete regression of the ciliary body tumor was achieved with improvement of best-corrected visual acuity (BCVA) following cataract surgery. A case of immunohistopathological biopsy proven that bilateral optic nerve infiltration of mantle cell lymphoma was treated successfully with a series of bilateral intravitreal MTX and systemic ibrutinib.

**Intraocular T cell lymphoma.** Biopsy-proven primary vitreoretinal natural killer/T cell lymphoma with breast involvement resolved with chemotherapy, intravitreal MTX, and ocular radiotherapy. Two patients with ocular involvement following...
systemic natural killer/T cell lymphoma achieved complete remission after single injection of intravitreal MTX. Another patient who presented with intraocular T cell lymphoma as a manifestation of mycosis fungoides was also successfully treated with intravitreal MTX. A patient who was diagnosed to have NK/T cell lymphoma of the testes, developed nasopharyngeal (underwent surgical resection) and ocular metastasis post orchiectomy. The patient achieved complete remission following serial injections of MTX in both eyes, intravenous MTX, and whole-body radiation therapy. The intravitreal dose may be effective as a palliative, vision-restoring measure in patients with systemic T cell lymphoma with ocular involvement.

**Ocular leukemic infiltrates.** A retrospective study of 11 eyes of leukemia with ocular tumor infiltration undergoing serial intravitreal MTX injections showed clinical resolution of the inflammatory response with regression of tumor cell infiltrates. In another report, a case of unilateral iris and ciliary relapse of acute lymphoblastic leukemia was successfully treated with intravitreal MTX with complete regression.

**Acute exudative polymorphous vitelliform maculopathy.** Acute exudative polymorphous vitelliform maculopathy (AEPVM) following cutaneous melanoma which was refractory to oral prednisolone, intravitreal triamcinolone, and bevacizumab showed complete resolution of subretinal fluid with significant gain of vision with a single dose of intravitreal MTX.

**Monitoring of therapy.** Serial optical coherence tomography (OCT) scans can be used to monitor patients treated with intravitreal MTX for PVRL. OCT features at initial visit (vitreous cells, subretinal infiltration, subretinal hyperreflective infiltration, outer retina fuzzy borders, pigment epithelium detachments, and subretinal fluid) showed resolution on serial OCT (except vitreous cells) with serial injections of intravitreal MTX.

A high IL10/IL6 ratio from the aqueous humor has been used for the diagnosis of intraocular lymphoma. Serial decrease in IL-10 and IL10/IL6 ratio has been observed with serial injections of MTX and thus can aid in monitoring therapy. A recent case report showed disappearance of MYD88 L265 P mutation from the aqueous samples of both the eyes of a case of PVRL on serial injections of intravitreal MTX and this could also be a possible tool for monitoring disease course in the future.

Until 2006, the only indication of use of intravitreal MTX was intraocular lymphoma. Hardwig et al. subsequently evaluated its efficacy in ocular diseases other than ocular lymphoma. In this retrospective series, seven eyes with posterior uveitis, five eyes with proliferative diabetic retinopathy and tractional retinal detachment (TRD), and one patient each of epithelial downgrowth and idiopathic fibrovascular proliferation were studied. Improvement in visual acuity was seen in most patients. Visual decline in four patients was attributed to the natural history of the disease.

**Uveitis.** Systemic MTX has been widely used in different ocular inflammatory conditions. Local therapy has also been found to be effective in cases of posterior noninfectious uveitis. In a pilot study by Taylor et al. on cases of unilateral noninfectious uveitis with raised intraocular pressure (IOP), long periods of remission were seen with a single dose of intravitreal MTX (400 μg/0.1 mL). Relapse was seen in one-third of the patients at a mean of 4 months and were reinjected with the same dose and showed similar remission. A similar multicentric study by the same author using intravitreal MTX as a first-line therapy for noninfectious uveitis found a good response in 30/38 eyes. There was a relapse in eight eyes at a median of 3 months and they were reinjected with same dose. Overall, an extended period of remission of over 17 months was observed. Out of 14 patients also taking systemic therapy, dose reduction could be achieved in eight patients. However, lack of control groups or comparison with standard treatment limits the utility of this study. Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy (MERIT) trial is a multicentric, randomized, interventional study which compares the efficacy of intravitreal ranibizumab (0.5 mg), MTX (0.4 mg), and dexamethasone implant (0.7 mg), and the results are expected in the end of 2021. The results of this randomized study could help us better in knowing the efficacy of MTX in uveitis.

**Choroidal tuberculoma.** Two case reports show gross reduction in the size of the tuberculoma and improvement of visual acuity following intravitreal MTX. Another case which developed paradoxical worsening of granuloma, exudative retinal...
detachment, and new yellowish white subretinal lesions on antitubercular therapy was managed with high-dose steroids, intravitreal MTX, and ranibizumab.52

**Tubercular serpiginous-like choroiditis.** A case of presumed tubercular serpiginous-like choroiditis unresponsive to anti-tubercular therapy (ATT), corticosteroids, and azathioprine was reported to develop an extended remission of over 24 months with two intravitreal MTX injections 1 month apart.53 In another case series, choroidal lesion healed with a single dose of intravitreal MTX in all the three eyes with improvement in visual acuity in two.54 Two patients of tuberculosis-related uveitis underwent intravitreal MTX in one eye at Week 8 of antitubercular therapy. Both patients showed resolution of leakage on fundus fluorescein angiography (FFA) from optic disk, reduction of vitritis, and slight reduction of macular edema.55 Thus, intravitreal MTX may prove to be effective in reducing inflammation even in cases of infective uveitis provided administered after adequate antimicrobial therapy.

**Behcet’s disease.** The role of intravitreal MTX in refractory Behcet’s disease was studied in seven patients who failed to respond to conventional treatment and had raised IOP with steroid injections. After a mean of 4.3 injections (400 μg/0.1 mL every month), six patients showed significant improvement in visual acuity and four patients had considerable decrease in fluorescein leakage. Intravitreal MTX was also associated with a significant reduction of IL-6 and IL-8 levels.56

A nonrandomized comparative study compared the effectiveness of intravitreal MTX (400 μg/0.1 mL) and retrobulbar triamcinolone acetonide (40 mg/mL) in 31 adult patients with bilateral disease. Intravitreal MTX was injected into the right eye, and retrobulbar triamcinolone acetonide was injected into the left. Pre-injection data, such as anterior chamber reaction, vitreous cells, IOP, and BCVA, were comparable between the groups. Patients were examined 1 week after the injection and monthly for a period of 6 months. There was no statistically significant difference between both the groups in terms of visual acuity, anterior chamber reaction, or vitreous activity; however, post-injection IOP was elevated in two eyes in the triamcinolone group which was adequately managed with topical glaucoma medications.57

**VKH.** There is a single case report which shows the efficacy of a single dose of intravitreal MTX (400 μg/0.1 mL) in a case of Vogt-Koyanagi-Harada disease (VKH) which was previously treated with oral prednisolone and mycophenolate mofetil, subcutaneous triamcinolone, and subcutaneous adalimumab.58 The patient suffered from bilateral panuveitis and was treated with oral prednisolone, mycophenolate mofetil. Two doses of subtenon triamcinolone and subcutaneous adalimumab were also administered earlier. The patient was intolerable to steroids and developed hepatotoxicity to mycophenolate. Intravitreal MTX was injected in both eyes which led to the significant improvement of vision, and this was followed by cataract surgery and intravitreal fluocinolone implant. In this case, intravitreal MTX reduced inflammation; however, as it is a single-case study, we cannot fully comment on the efficacy of this approach and the duration of action of the intravitreally injected drug.

**MFC with CNV.** Single dose of intravitreal MTX in a patient of multifocal choroiditis (MFC) with recurrent inflammatory choroidal neovascular mem bran (CNV) following multiple doses of intravitreal ranibizumab showed significant improvement of vision and no recurrence for over 20 months.59

**Epstein–Barr virus necrotizing retinitis.** Intravitreal MTX was found to be effective in a case of necrotizing retinitis with Epstein–Barr virus (EBV)-positive ocular fluid which was on oral methylprednisolone for 20 years for interstitial pneumonia. The disease did not respond to systemic ganciclovir or acyclovir; however, a single dose of intravitreal MTX showed significant clinical improvement with decrease in copy number of EBV-DNA.60

**CMV retinitis.** Intravitreal MTX with oral valganciclovir showed profound improvement in a patient with bilateral CMV retinitis and cystoid macular edema (CME) along with disk edema of the right eye following bone marrow transplant for acute myeloid leukemia (AML). BCVA was counting fingers in the right eye and 20/100 in the left. Serial intravitreal MTX was administered only in the right eye (worse eye). BCVA improved in both eyes (20/200 right eye (OD) and 20/63 left eye (OS)); however, CME resolution was apparent only in the right eye along with resolving disk edema, whereas it was persistent in the left eye on oral valganciclovir treatment alone.61
**Proliferative vitreoretinopathy.** MTX has shown to have a promising role in treatment and prevention of proliferative retinopathy due to its anti-inflammatory and antifibrotic activity. Elliot *et al.* studied the efficacy of serial intravitreal MTX (400 μg/0.1 mL) in cases with pre-existing PVR (PVR C or higher) and those at high risk to develop PVR following vitrectomy with silicon oil tamponade. The first dose was given intraoperatively followed by weekly doses for 2 months and one at third month (10 doses). However, 80% of the patients had attached retina at the end of 39 months and median visual acuity of 20/200.62 Another retrospective study showed 100% reattachment in five patients with severe PVR and recurrent detachment who underwent post vitrectomy serial injections of 200 μg/0.05 mL intravitreal MTX for 10 weeks.63 Denstedt *et al.* report a patient who suffered inadvertent needle injury during acupuncture and developed retinal detachment, vitreous hemorrhage, and a large area of bare sclera nasal to the disk. Following vitreoretinal surgery, the patient developed PVR proliferation under oil and underwent nine doses of intravitreal MTX (200 μg/0.05 mL, 2–3 weekly). This stabilized the preretinal fibrosis, and the patient attained a visual acuity of 20/40 at final follow-up.64

Sadaka *et al.* published their retrospective study of retinal detachment complicated with PVR who underwent vitrectomy with oil tamponade. MTX infusion (40 mg of drug in 500 mL balanced saline solution) was administered during vitrectomy. Retinal reattachment rate was 90% with 66% gaining vision better than 20/200.65 Gain Understanding Against Retinal Detachment (GUARD) trial, which is a multicentric clinical trial on the efficacy of serial MTX injection (0.8 mg), has been initiated and the results are expected next year.66 Intravitreal MTX in a cumulative dose of up to 1200 μg was found to be safe in silicone-filled eyes.67

**Recurrent epithelial downgrowth.** Two case reports demonstrate complete resolution with no recurrence in recurrent epithelial downgrowth. In one report, 12 weekly doses were used,68 whereas the other report showed complete disappearance after 6 weekly doses.69

**Diabetic macular edema.** A prospective pilot study, which compared three monthly injections of a combination of intravitreal, bevacizumab, and MTX with intravitreal bevacizumab alone, demonstrated no significant additional benefit of adding MTX.70 In another prospective study, the use of three or more intravitreal MTX injections in eyes with persistent diabetic macular edema (DME) resulted in reduction of central macular thickness (CMT) in a significant proportion of eyes. Significant visual improvement was found only in 16.6% of eyes.71

**Exudative age related macular degeneration (AMD).** Two patients with refractory CNV secondary to age related macular degeneration (AMD) after treatment with a single dose of intravitreal MTX showed resolution of subretinal fluid with improvement in vision.72 A pilot study on seven eyes evaluating the combination of a single dose of intravitreal MTX with multiple intravitreal bevacizumab showed significant visual improvement but insignificant reduction of CMT from baseline. The authors propose that the addition of intravitreal MTX in neovascular AMD may enhance the therapeutic effect of bevacizumab and may reduce the development of a fibrous component and disciform scar.73

**Retinoblastoma.** There is a report of using serial intravitreal MTX (according to lymphoma protocol) in five eyes with retinoblastoma. Most of these eyes showed either partial or complete remission of vitreous seeds, subretinal seeds, and small retinal foci.74

**Side effects.** Corneal epithelial toxicity is a common side effect in patients receiving repeated intravitreal MTX. Other side effects that have been described are cataract, glaucoma, maculopathy, vitreous hemorrhage, optic atrophy, sterile endophthalmitis, and epiretinal membrane formation.19–21

**Corneal epithelial toxicity.** Jeong *et al.* have published a retrospective study to determine incidence, risk factors, and treatment of corneal epithelial toxicity following intravitreal MTX. *In vitro* analysis of cytotoxic effect of MTX on corneal epithelial cells was also performed. The incidence of epitheliopathy was found to be 22.7% after an average number of 5.7 injections. The average time to the development of epitheliopathy was 5.7 weeks from the first injection. The most common findings were superficial punctate erosions, central epithelial defects, and epithelial sheet-like opacity. Patients who used concurrent antiglaucoma medications were found to be at a higher risk of developing epitheliopathy. Epitheliopathy resolved in all cases in which either the MTX was stopped, or patients

---

6 journals.sagepub.com/home/oeo
were started on topical lubricants, autologous serum, topical antibiotics, topical steroids, therapeuetic contact lens, oral folic acid supplementation, or topical antiviral agents. In vitro study revealed that MTX could suppress proliferation, induce apoptosis, and generate oxidative stress in corneal epithelial cells. Folinic acid supplementation in vitro showed the preservation of corneal epithelial cell viability and inhibited apoptosis. Zhou et al. found a reduction in incidence of keratopathy on changing to monthly intravitreal injections after remission of disease.

A case report mentions significant improvement in corneal toxicity within 1 week of commencing oral folic acid (1 mg daily). Pranita et al. in a report successfully treated the epithelial toxicity with topical chloramphenicol, loteprednol, cyclosporine, folinic acid (5 mg/mL), and oral folic acid 5 mg once a day. This is the only case report that has used topical folinic acid drops for MTX-induced corneal toxicity. Ghasemi Falavarjani et al. found that there were no significant effects on the endothelial cell density, coefficient of variation, average cell area, hexagonality, and central corneal thickness measurements before and after injections.

Resistance to MTX. Resistance to multiple intravitreal doses of MTX in PVRL has also been seen. The mechanism of resistance is believed to be due to decreased expression of reduced folate carrier (RFC) and folate binding protein (FBP) and increased expression of multidrug resistance protein (MRP). A large sample size is required to hypothesize the mechanism of resistance to MTX. Such single reports could be coincidental without any relationship. In a case report where resistance to MTX was suspected, vitrectomy was undertaken which led to the resolution of disease for more than 2 years.

Limitations. Intravitreal and systemic MTX is the drug of choice in PIOL and PCNSL. However, randomized controlled trials and prospective studies are very limited in literature and most studies are single-case reports, case series, or retrospective studies without a systematic methodology. Studies with larger sample size are usually cases of PIOL/PCSNL with different treatment regimens which are not comparable.

Sirolimus
Sirolimus (rapamycin) is a macrolide antibiotic produced by a strain of Streptomyces hygroscopicus. It acts by inhibiting the mammalian target of rapamycin (mTOR) which interrupts T_{HH} activation and clonal expansion. Sirolimus also inhibits IL-2, IL-4, and IL-5 by both calcium-dependent and -independent pathways. Sirolimus was first approved by FDA for the treatment of lymphangioleiomyomatosis. Sirolimus has also been used to coat corneal stents to prevent restenosis due to its antiproliferative effect. Its ocular use has been mostly limited to intravitreal or subconjunctival injections for the treatment of noninfectious posterior uveitis.

Animal studies. Intravitreal sirolimus (10 mg) was found to be present in vitreous even 21 days after injection in horse eyes. No ocular toxicity was seen on histopathological evaluation after 21 days. Different doses of intravitreal sirolimus (20–1000 μg) were injected in rabbit eyes, and no histopathological toxic effects were seen. Doses of 50, 200, and 1000 μg showed slight decrease in amplitude on ERG but this was not dose-related. Doses up to 220 μg in rabbits and 352 μg in humans were well tolerated without any adverse effects in a study by Mudumba et al. The drug persisted for around 90 days in the vitreous of rabbits, and very trace amounts (1.99 ng/mL) were seen in the blood sample of humans at Day 7 after the 352 μg dose. NMDA-induced retinal damage in rats was successfully attenuated by intravitreal sirolimus by the activation of the ERK pathway in retinal Müller cells, demonstrating its neuroprotective property. Intravitreal sirolimus also reduced the NMDA-induced inflammation and capillary degeneration in rat eyes.

Drug delivery systems. PLGA sirolimus implants showed decreased inflammatory scores and significant reduction of proteins even after 35 days in treated eyes with no toxic effects in rabbit eyes. Abud et al. evaluated the in vivo and in vitro toxicity (rabbit eyes) of liposomal-encapsulated sirolimus (LES) and found them to be stable even after 3 months. ARPE-19 cell viability and terminal deoxynucleotidyl transferase nick-end labeling (TUNEL) assay were comparable between LES, empty liposomes, and balanced salt solution (BSS) groups, and glial fibrillary acid protein (GFAP) immunohistochemistry did not show activation of Müller cells. This shows that liposome-encapsulated sirolimus is a safe alternate drug delivery system for sustained effect. Sirolimus-loaded polymeric micelles also showed promising results in experimental autoimmune-induced uveitis (EAU) in rat models. Engineered porous
silicon crystals enable sustained drug delivery; additionally, these allow real-time monitoring of drug release in the form of color change which can help note the real-time drug concentration in the vitreous.\textsuperscript{93,94}

\textit{Noninfectious posterior uveitis.} Sirolimus as a therapeutic Approach for Uveitis (SAVE), SAVE-2, and Sirolimus Study Assessing Double-Masked Uveitis Treatment (SAKURA) were landmark trials that studied the use of intravitreal sirolimus in noninfectious uveitis patients. SAVE compared the efficacy and ocular tolerability of subconjunctival (1320 \( \mu \text{g} \)) and intravitreal (352 \( \mu \text{g} \)) injection of sirolimus at 6 months.\textsuperscript{95} The injection was administered at Days 0, 60, and 120 in each group. There was significant reduction of vitreous haze from baseline in both groups with 60\% showing a reduction of two steps or more and 40\% showing a one-step reduction; however, on comparing the two groups, the outcome was not significant. The dose of systemic corticosteroid could be reduced to less than 10 mg/day in most patients of both the groups. One-third of the patients showed a visual gain at the end of 6 months, 50\% had stable vision, and 20\% had lost one more line of visual acuity. However, this outcome was not statistically significant when compared to baseline and between the two groups. Reduction in CMT was noticed at 3 months in most patients. This reduction was not maintained at sixth month with 30\% having worsening of macular edema. Both the doses were well tolerated with local injection site hyperemia and chemosis in patients taking subconjunctival injections. Vitreous floaters were the most common adverse event (AE) of the intravitreal dose. Following the 6-month outcome study of SAVE trial, 12-month outcome was also studied in which the patients of the respective groups were administered injections as and when needed with a minimum gap of 2 months between two doses till 12 months.\textsuperscript{96} The overall treatment frequency was two injections/eye in the intravitreal group and 2.36 injections/eye in the subconjunctival group. The results were similar to the 6-month study with 70\% showing two or more step reduction of vitreous haze and 36\% gaining greater than one line of visual acuity. Corticosteroid-sparing effect was seen in most patients with non-significant change in CMT.\textsuperscript{97}

SAV-E-2 studied the effect of two different doses of intravitreal sirolimus (monthly 440 \( \mu \text{g} \) and two monthly 880 \( \mu \text{g} \)).\textsuperscript{98} The reduction of vitreous haze was significant from baseline but not significant between the groups. Both groups did not show significant change in BCVA or CMT from baseline. There was a significant decline in the number of patients continuing corticosteroid or immunomodulators from baseline.

SAKURA study was a double-masked 6-month study which compared different doses (44, 440, and 880 \( \mu \text{g} \)) of a proprietary formulation of sirolimus injected intravitreally at 2-month intervals (Days 0, 60, and 120).\textsuperscript{99} A significantly higher proportion of patients in the 440 \( \mu \text{g} \) group achieved nil vitreous haze at fifth month compared to the other two groups. Visual acuity was preserved, and corticosteroid dose was successfully tapered off in all three groups.\textsuperscript{100} Another study which combined the results of SAKURA 1 and SAKURA 2 studies was carried out by Merrill \textit{et al.}\textsuperscript{101} In this study, the 880 \( \mu \text{g} \) dose group was removed and the other two doses were compared. The vitreous haze 0 response rate was significantly higher in the 440 \( \mu \text{g} \) dose group. BCVA was stable in both the groups, and corticosteroid was tapered successfully and equally in both groups.

\textit{Geographic atrophy.} Petrou \textit{et al.}\textsuperscript{102} studied the safety and efficacy of intravitreal sirolimus (440 \( \mu \text{g} \)) in geographic atrophy and found new peripher- sional changes that were associated with accelerated retinal thinning around the geographic atrophy with no benefit in relation to change in central retinal thickness (CRT) or BCVA. Another similar study with a larger sample size found no change in the progression rate of GA area or visual acuity. Three patients developed sterile endophthalmitis which prompted early stoppage of the study due to lack of benefit.\textsuperscript{103}

\textit{Wet AMD.} A pilot study on the efficacy of intravitreal sirolimus compared the 440 \( \mu \text{g} \) (two monthly injections) with bevacizumab (1.25 mg) or aflibercept (2 mg).\textsuperscript{104} Visual acuity outcome was similar in both groups despite having a significantly better reduction in central macular thickness in the anti-vascular endothelial growth factor (anti-VEGF) group. Serious ocular AEs, such as central retinal artery occlusion, larger subretinal hemorrhage, and anterior uveitis, with elevated IOP in the sirolimus group merit further evaluation of the drug. A report that compared two monthly intravitreal sirolimus (440 \( \mu \text{g} \)) with monthly antiVEGF injections in patients with chronic neovascular AMD and persistent retinal fluid showed significant reduction in central subfield thickness and subretinal fluid. However, the...
change in visual acuity and intraretinal fluid remained the same.\textsuperscript{105} Another study showed that a combination of sirolimus and aflibercept showed better resolution of intraretinal and subretinal fluid compared to aflibercept monotherapy, but the reduction of CMT was insignificant.\textsuperscript{106}

**Diabetic macular edema.** The safety and tolerability of local sirolimus injections was studied by injecting a single dose of different concentrations of intravitreal (44, 110, 176, 264, or 352 μg) and subconjunctival (220, 440, 880, 1320, or 1760 μg) sirolimus in patients with diabetic macular edema, and outcomes were observed at 90 days.\textsuperscript{107} Serious AEs were not seen in both groups. There was improvement in visual acuity and central macular thickness in both the groups; however, since this was a phase I study, the significance was not evaluated.

**Cyclosporine**

Cyclosporine is a calcineurin inhibitor and a potent immunomodulatory agent which acts mainly by inhibiting the production of cytokines (mainly IL-2) involved in the regulation of T cell activation.\textsuperscript{108} Oral cyclosporine was first FDA-approved in 1983 for the treatment of organ rejection in solid organ transplantation. Topical formulation of cyclosporine was FDA-approved in 2003 under the brand name Restasis (0.05%) for chronic dry eye.\textsuperscript{109} Many animal studies have been conducted to study the efficacy, toxicity, and different modes of drug delivery. However, there are no human studies or case reports till date.

**Animal studies.** Several animal studies provide evidence of intravitreal administration showing good immunosuppressive action in experimentally induced uveitis. A study by Liversidge et al.\textsuperscript{110} showed that intravitreal cyclosporine A (CsA) suppressed the production of major histocompatibility complex (MHC) class 2 (I-a) antigen-inducing lymphokines thereby inhibiting intraocular inflammation. A study by Jaffe et al.\textsuperscript{111} using intravitreal sustained release CsA in rats sensitized by intraocular inoculation of mycobacterium tuberculosis showed significant decrease in inflammation, reduced b-wave suppression, and reduced inflammatory changes on histopathological examination of cyclosporine-treated eyes compared to untreated eyes. High concentration of the drug was measured in the vitreous cavity even at 6.5 months, and trace amounts were present in the peripheral blood.

In a study by Wang et al., intravitreal injection of CsA (42 ng/2 μL) in streptozocin-induced diabetic rats showed attenuation of retinal expression of inflammatory mediators [IL-1 beta and transforming growth factor (TGF)] and reduced edema and disorganization of the retinal layers. In a subgroup of this study, where recombinant home mobility group box 1 (HMGB 1) was injected along with CsA, suppression of HMGB 1 (proinflammatory mediator) was also noted thereby proving a protective effect on the retina.\textsuperscript{112} In another study by Zong et al., the a-wave and b-wave amplitudes of diabetic rats treated with cyclosporine were significantly higher than untreated diabetic rats. The ultrastructural changes seen on electron microscopy were also less severe.\textsuperscript{113} A study by Karakücük et al.\textsuperscript{114} showed that intravitreal cyclosporine could also be used as an adjuvant to radiotherapy to inhibit intraocular proliferation following penetrating ocular injury in rabbits. Jong et al. studied the effect of intramuscular (25 mg/kg) and intravitreal CsA (5 mg) administered before and after the induction of herpes simplex (HSV) uveitis and found that a combination of intramuscular and intravitreal CsA before the induction of uveitis significantly reduced the uveitis.\textsuperscript{115}

**Retinal toxicity.** Grisolano and Peyman\textsuperscript{116} on comparing two different concentrations of cyclosporine found that 100 μg of intravitreal cyclosporine did not show any toxicity; however, the 200 μg showed adverse histologic changes in the retina in the form of patchy loss of outer segments of the retina. Alghadyan et al.\textsuperscript{119} studied the toxicity of liposomal-bound cyclosporine in albino rats and found no adverse histological changes in doses up to 500 μg.

**Immunosuppressive agent in animal studies.** Intravitreal cyclosporine has also been used to make \textit{in vivo} retinoblastoma models using Y79 cells injected in rats as this induced partial immunosuppression which allowed better growth of the tumor cells in the rat model.\textsuperscript{117} The same was observed in another study in which human retinal pigment epithelial (RPE) xenografts injected intravitreally in rabbits survived longer in eyes with local immunosuppression using intravitreal cyclosporine implying that T lymphocytes were responsible for rejection and immunosuppression and a specific T cell inhibitor-like cyclosporine could prolong the survival of these xenografts.\textsuperscript{118}
Drug delivery. Various sustained release drug delivery systems, such as liposome-bound drug embedded in copolymers (PLGA), biodegradable copolymer microspheres, or oleogel rods with biocompatible gelators, have been studied. Half-life of free cyclosporine was found to be about 6 h, and liposomal-bound cyclosporine was around 3 days. Sustained release intravitreal implants can maintain therapeutic levels from 10 weeks to 3 years as shown by various studies. Intravitreal implants can maintain a concentration of 500 ng/mL with an implant containing 10 μg over a period of 6 months or 0.06 ± 0.02 μg/mL with an implant containing 100 μg over a period of 10 weeks. Intravitreal biodegradable implant of cyclosporine in experimental uveitis showed that the device can maintain approximately 102 ng/mL at 1–3 weeks, 491 ng/mL at 4–10 weeks, and 257 ng/mL at 14 weeks and effectively reduce intraocular inflammation with no toxicity.

In 2006, He et al. showed that intravitreal injection of biodegradable (PLGA) copolymer microspheres containing CsA in experimental uveitis in rabbits decreased intraocular inflammation significantly and could maintain a therapeutic concentration for at least 65 days in disease-related tissues, such as choroid, retina, iris, and ciliary body. However, there was reversible depression of b-wave amplitude on ERG. Pearson et al. also showed reversible decrease in b-wave amplitude and lens opacification in rabbits which were not seen in Cynomolgus monkeys. Similar reversible depression of b-wave amplitude was noted in another study of sustained release of 100 μg CsA with 2 mg dexamethasone using an intravitreal device in contrast to plain dexamethasone-releasing device. No changes were seen on histological or clinical examination in both groups. Dong et al. studied the effects of oral CsA (15 mg/kg), intravitreal biodegradable cyclosporine implant (2 mg), non-medicated implant, and controls in experimental uveitis. The biodegradable implant showed better control of inflammation, less systemic toxicity, and less depression of b-wave amplitudes compared to the other three groups.

Intravitreal cyclosporine has been studied as a treatment modality in recurrent uveitis in horses. Gilger et al. showed that CsA implants did not completely eliminate the development of a recurrent experimental inflammatory episode in horses, but the duration and severity of inflammation, cellular infiltration, tissue destruction, and proinflammatory cytokines levels were significantly less in the eyes implanted with the CsA device.

Tacrolimus

Introduction. Tacrolimus (FK506) is an antibiotic macrolide isolated from Streptomyces tsukubensis and was used to prevent allograft rejection in the liver, kidney, lung, and heart transplantations. Tacrolimus forms a complex with a specific FK506-binding protein called immunophilin and inhibits the activation of calcineurin, a Ca2+-dependent enzyme, and exhibits various pharmacological actions. The immunosuppressive action is manifested by inhibiting the nuclear factor of the activated T cell to suppress the transcription of IL-2. Other off-label indications of oral tacrolimus include Crohn disease, graft versus host disease (GVHD), myasthenia gravis, and rheumatoid arthritis.

Animal studies. A study by Passos et al. showed that doses of 10 and 50 μg are non-toxic to rabbit eyes on the basis of clinical, ERG, and light microscopy findings, whereas doses of 100 and 250 μg led to transient vitreous opacities and 500 and 1000 μg of tacrolimus were toxic to retina. The group which received 500 and above showed decreased amplitude of b-wave in ERG and mild disorganization of retina on light microscopy. Another study showed that 50 μg is toxic to the retina as swelling of the mitochondria of photoreceptors could be seen on electron microscopy in rabbit eyes, whereas 25 μg or less was safe.

Neuroprotection. Tacrolimus may also have a neuroprotective effect and improve axonal regeneration following damage to peripheral nerve fibers. In a study by Rosenstiel et al., application of tacrolimus intravitreally immediately after optic nerve crush (both in vivo and vitro) induced elongation of regenerating fibers for about 1.2 mm around the lesion. Intravitreal tacrolimus also reduces Akt and Bad dephosphorylation which are proapoptotic factors seen during ischemic damage of rat retina.

Experimental autoimmune–induced uveitis. In tacrolimus-treated eyes, interferon gamma and tumor necrosis factor (TNF) alpha were inhibited. Another study showed that intravitreal injection of 10 μg of tacrolimus was effective in suppressing ongoing EAU in rats. They also
found that genes for molecules associated with neuroprotection (estrogen receptor, erythropoietin receptor, gamma-aminobutyric acid receptor, protein kinase C, glial cell-line-derived neurotrophic factor receptor, fibroblast growth factor, and neuropeptide Y receptor) were upregulated in the retina with intravitreal tacrolimus.

Turgut et al. evaluated the efficacy of intravitreal tacrolimus in the treatment of experimental PVR and demonstrated significantly decreased levels of TGF-β, platelet-derived growth factor, and fibroblast growth factor which are involved in PVR development.

**Drug delivery.** A study evaluated the efficacy of a biodegradable polymeric scleral plug containing tacrolimus in a rabbit model for chronic uveitis. The device maintained constant levels of 480–350 ng/g of tacrolimus in the vitreous for 4 weeks and it was effective in suppressing inflammation for at least 6 weeks. Another study showed that treatment of EAU with intravitreal injection of liposomal tacrolimus was able to deliver 200 ng/day of tacrolimus for 14 days and significantly reduced intraocular inflammation. No toxic effects could be seen on ERG. Tacrolimus-loaded PLGA implants and tacrolimus in functionalized silica nanoparticles with 3-aminopropyltriethoxysilane (MSNAPTES) are other safe and effective intraocular drug delivery systems that can provide a sustained intraocular concentration of tacrolimus.

**Biologics**
The following biological agents have been used intravitreally either in human patients/subjects or in animal models (Table 2):

- Infliximab.
- Adalimumab.
- Rituximab.
- Etanercept.
- Natalizumab.
- Golimumab.

**Infliximab**
Infliximab is a chimeric monoclonal IgG1 antibody made up of human constant and murine variable regions and inhibits TNF (TNF-alpha blocker). It has used as an intravenous agent since 1994 for diseases, such as rheumatoid arthritis, inflammatory bowel disease, and ankylosing spondylitis.
spondylitis,\textsuperscript{144} and other systemic inflammatory diseases. However, the first report of its use as an intravitreal agent came in 2009 when it was used in the cases of neovascular AMD not responding to antiVEGF.\textsuperscript{145} It was FDA-approved first as an intravenous agent for Crohn’s disease in 1998 and later for diseases, such as rheumatoid arthritis, ulcerative colitis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis.\textsuperscript{146} Infliximab acts by binding to TNF receptors with high affinity and disrupts the proinflammatory cascade signaling which leads to downregulation of proinflammatory cytokines, such as IL-1, IL-6, and so on, reduction of lymphocyte and leukocyte migration, apoptosis of TNF producing cells (activated monocytes), and reduction of endothelial adhesion molecules and acute phase proteins.\textsuperscript{147} The molecular weight of infliximab is 149 kD, and its vitreous half-life following an intravitreal injection was found to be 6.5–8.5 days in animal models.\textsuperscript{148}

**Animal studies.** Many studies have shown that intravitreal doses of up to 2 mg/0.1 mL were well tolerated in rabbit eyes.\textsuperscript{140–153} Giansanti et al. showed significant edema of the nerve fiber layer at a dose of 3.3 mg which was not seen at lower doses. However, there was no electrophysiological change at this dose.\textsuperscript{149} Another study by Theodossiadis et al.\textsuperscript{151} observed perilimbal hyperemia and vitreous flare on Day 5 after injection of 8 mg or higher. Significant reduction in amplitude of b-wave was seen in doses of 5 mg and higher and ERG responses to 30 Hz flicker stimulus were found to be the most sensitive tool to detect retinal toxicity. Histopathological changes, such as edema of the ganglion cell layer and nerve fiber layer, microcysts in the inner layers and thickening of the outer layers, were also evident in 5 mg and higher doses. A recent study to look for dose-dependent retinal safety in albino rats showed no significant histological or electrophysiological changes at a dose as high as 7.5 mg/0.1 mL. The only significant effect at this dose was increased GFAP immunoreactivity in the Müller cells of peripheral retina which was attributed to retinal stress response.\textsuperscript{150} Serial injections (2–3) of 2 mg intravitreal infliximab also did not show any significant adverse changes in the histopathology or electrophysiology of the retina even after 90 days.\textsuperscript{154} The immunoreactivity of infliximab can be maintained over 6 weeks when stored at 4°C and is also suitable for compounding which could be a cost-effective alternative.\textsuperscript{155}

Two studies provided evidence of suppression of ocular inflammation in experimental endotoxin-induced uveitis.\textsuperscript{156,157} A study on experimental endophthalmitis using *S. epidermidis* showed that infliximab was as effective as dexamethasone in controlling inflammation when injected intravitreally along with vancomycin.\textsuperscript{158} In contrast to this, two studies which compared intravenous and intravitreal infliximab showed significantly better control of inflammation with the intravenous regimen. One of these studies showed no change with intravitreal dose\textsuperscript{159} while the other showed exacerbation of inflammation with intravitreal injection.\textsuperscript{160} Studies on experimental laser-induced choroidal neovascularization showed dose-dependent decrease in CNV activity with the injection (1.5 mg – 11% reduction and 15 mg – 68%).\textsuperscript{161} However, another study in which doses from 10 to 320 μg were given, response was seen in lower doses (up to 40 μg), and higher doses did not have any effect (80 and 320 μg). Expression of markers, such as VEGF, TGF-β, vWF, syndecan-4, and sulfated glycosaminoglycans, were also reduced in doses up to 80 μg. High-dose infliximab also showed a 20% decrease in the viability of endothelial cells.\textsuperscript{162} An animal study on the use of intravitreal infliximab was done to assess the cytokine levels associated with PVR (TNF-A, IL-1, IL-6, PDGF, and TGF-B). Significant reduction of all cytokines except TGF-B was seen in the enucleated vitreous.\textsuperscript{163}

**Human studies.** TNF-alpha inhibitors have been widely used in the treatment of uveitis and is currently being considered as the third step after steroids and immunosuppressants in the step ladder management of uveitis. Intravenous infusion is the most common mode of delivery. Since this can potentially have systemic side effects, intravitreal drug delivery has also been explored. Doses between 1 and 1.5 mg/0.1 mL have been used in different studies with equivocal results. Farvardin et al. studied the response of a single intravitreal injection of 1.5 mg/0.1 mL in eyes of chronic persistent noninfectious uveitis and found significant improvement in visual acuity, reduction in central macular thickness, and vitreous haze. However, this effect was temporary (lasted about 4 weeks) with relapse of the disease and visual acuity and central macular thickness returning to the preinjection status at 6 months.\textsuperscript{164,165}

**Behcet’s disease.** Hamza et al. had studied the effect of intravitreal infliximab in 20 eyes of refractory uveitis in Behcet’s disease. Three injections
of 1 mg/0.1 mL 6 weeks apart were administered. Significant improvement in BCVA, central foveal thickness (CFT), and vitreous haze was seen in these patients, and patients with retinitis, vasculitis, and papillitis drastically improved during the course of the disease. No significant electrophysiological or ocular AEs were noted. Another study by Markomichelakis et al. using a single intravitreal dose (1 mg/0.05 mL) showed significant improvement in BCVA, anterior chamber cells, vitreous haze, and CRT. Retinitis and vitritis cleared after 14 days of injection in most eyes. CME was the most resistant of all and resolved in only 2 out of 11 patients. The maximum follow-up period was only 30 days and hence long-term outcomes could not be deduced. A recent long-term prospective study on the use of monthly intravitreal infliximab in Behcet's disease with active posterior uveitis was analyzed. Nine monthly injections of intravitreal infliximab (1 mg/0.05 mL) was administered in patients with vitritis, vasculitis, retinitis, and papillitis with proven Behcet's disease and on systemic steroids and immunosuppressants. Consecutive injections were administered only when there was clinical improvement or visual gain following each injection, and there was no evidence of adverse effects to the drug. Patients who did not improve with any dose were not given the next monthly dose of injection and were considered treatment failure. Of the 20 eyes of 14 patients who had participated in the study, 7 (35%) eyes had successful treatment of all nine doses, whereas 13 (65%) eyes were considered treatment failure. Four of these eyes had an exacerbation of the disease of which one patient had to undergo vitrectomy to control the disease. Nine eyes failed to be controlled over 6 months, and the estimated time of failure of these nine eyes was 3.3 ± 0.2 months. Of the eyes that underwent successful treatment with nine doses, there was significant visual gain (20/800 to 20/80) and vitreous haze grade. Vasculitis and retinitis had also resolved in three out of four eyes, and papillitis resolved in 1/1 eyes at 3 months. ERG showed no significance in photopic and scotopic b-wave amplitude and implicit time between baseline and final follow-up in those who received all nine doses.

**Pseudophakic CME.** A retrospective study of the Pan American Collaborative Study group on the effect of intravitreal infliximab (1 mg) in patients with refractory pseudophakic CME showed significant improvement in BCVA from 1.14 ± 0.59 logMAR at baseline to 0.51 ± 0.35 logMAR (p = 0.016) and reduction in CFT from 584 ± 159 microns to 327 ± 127 (p = 0.011) in seven patients at 6 months. All eyes had prior treatment with topical NSAIDs, topical intravitreal, or peribulbar corticosteroids or intravitreal antiVEGF. The average number of injections was 2.7, and there was only a single episode of uveitis in one patient which responded to topical steroids. Lack of control group limits the application of this study.

**Age-related macular degeneration.** The first study of intravitreal infliximab was done in patients with refractory wet AMD by Theodossiadis et al. in which two injections of infliximab (1 and 2 mg) were given 2 months apart. All three patients showed significant improvement in BCVA and reduction in CFT. One patient who was on anticoagulants developed spontaneous vitreous hemorrhage which resolved at 2 months. However, three more studies on its use in AMD have noted significant intraocular inflammation which required management ranging from topical steroids to vitrectomy without any improvement in the outcome of the disease. Freitas et al. studied the effect of a combination of intravitreal bevacizumab and infliximab in treatment-naïve CNV and found significant reduction in subretinal and intraretinal fluid and activity of CNV in five of six patients. Cataract progressed in four of five patients and one patient developed vasculitis and vitritis 1 month after the second injection.

**Diabetic macular edema.** A single retrospective study on the use of intravitreal TNF-alpha inhibitors in refractory DME showed no significant change in BCVA or CMT with the use of intravitreal infliximab. However, 42% (8/19) of the patients who were injected with 2 mg/0.05 mL developed severe uveitis and three of them needed vitrectomy. None of the patients in the 1 mg group developed uveitis.

**Side effects.** Ocular side effects of intravitreal infliximab can be immunogenic (uveitis) or retinotoxic (electrophysiological changes). A prospective study by Giganti et al. demonstrated increased complications with low-dose intravitreal infliximab (0.5 mg) when injected in two patients of CNV and two patients of DME. None of the patients showed improvement in BCVA, CFT, or activity of CNV, and all patients worsened on angiography. Three of the four patients developed optic disk leakage, one patient developed anterior chamber (AC) and vitreous cells with acute rise in IOP, and one patient developed vitreous opacities which persisted till 12 months.
Electrophysiological tests showed decline in amplitude and increase latency in all patients. Microperimetry showed a steady decline in all patients ranging from 20% to 73% from baseline. Three patients also developed systemic antibodies to infliximab (HACA). Other studies in literature have shown complications, such as anterior uveitis, vitritis, vasculitis, CME, and panuveitis with use of intravitreal infliximab. Adalimumab

Adalimumab is another TNF-alpha inhibitor and a fully human recombinant monoclonal antibody IgG1 which has similar mechanism of action to infliximab. It was first FDA-approved in the year 2002 for subcutaneous use, and the first reported use in literature was in the cases of juvenile rheumatoid arthritis. Its first intravitreal use was in the cases of refractory macular edema following noninfectious uveitis. The systemic half-life of adalimumab is 14 days and its molecular weight is 148 kDa.

Animal studies. Inflammation (AC reaction and vitreous cells), 30% reduction in amplitudes of a- and b-wave, and histological changes (inflammatory cell infiltration) were noted in rabbits with 1 mg dose. However, a similar study done 3 years later showed no such changes in doses up to 10 mg except for significant decrease in photopic-wave ERG response in the 10 mg dose. Two similar studies showed that doses up to 5 mg showed no adverse changes. A study to look for cytotoxicity and genotoxicity of 0.5 mg adalimumab in rabbits found no detectable toxicity up to 60 days of injection. Intravitreal adalimumab injected in rd10 mice (model of autosomal recessive retinitis pigmentosa) was found to prevent retinal degeneration in rats. Effect of bevacizumab and adalimumab in laser-induced CNV in rats was studied and demonstrated that adalimumab reduced the number of laser-induced grade 4 lesions by more than 50%; however, it was not as effective as bevacizumab.

Noninfectious uveitis. Hamam et al. studied the efficacy of intravitreal adalimumab (1.5 mg/0.03 mL) in 13 eyes with active noninfectious uveitis. Each eye was given seven injections (Day 0, 2 weeks, and then every month). The last assessment was done 1 month after the last dose (26 weeks). Treatment failure was observed in one eye, seven eyes showed significant gain of vision (>2 lines on ETDRS), and five gained one line. Five of eight eyes had complete resolution of CME, and three eyes with AC cells and nine eyes with vitreous haze had complete resolution of inflammation. FA score decreased in all patients from baseline and vascular sheathing was the first sign to respond followed by optic disk hyperfluorescence. No adverse electrophysiological changes were noted. Another study in patients with refractory CME did no show significant improvement in visual acuity or central macular thickness after three monthly injections and 6 months follow-up.

Behcet’s disease. Kheir et al. studied the efficacy of intravitreal adalimumab in patients of Behcet’s disease with breakthrough intraocular inflammation when on systemic adalimumab. Seven eyes of four patients were included in the study and a collective of 13 attacks were noted over a mean time of 4.1 months on systemic therapy. All 13 attacks resolved with intravitreal adalimumab, 3 attacks resolved with one injection, and 10 attacks resolved after more than one injection. VA returned to baseline in 4/6 attacks, AC cells resolved in 4/8 attacks, vitreous haze reduced in 11/12, and vascular leakage reduced in 5/7 attacks.

Pseudophakic CME. Farvardin et al. studied the efficacy of 1 mg/0.04 mL of intravitreal adalimumab in pseudophakic CME and found that none of the patients had significant difference in visual acuity or central macular thickness at 1 and 4 weeks. One eye developed severe ocular inflammation and IOP rise which could not be controlled on topical steroids and intravitreal antibiotics; hence, vitrectomy was done.

Macular edema due to other causes. A case series of seven patients with macular edema of different etiologies (two pseudophakic macular edema, two DME, two AMD, and one central retinal vein occlusion (CRVO)) were treated with intravitreal bevacizumab and 2 mg intravitreal adalimumab (one to four injections each). The study showed improvement in BCVA of more than three early treatment of diabetic retinopathy study (ETDRS) lines in four of seven patients, and none developed any systemic or ocular complication.

Studies on intravitreal adalimumab in neovascular AMD and diabetic macular edema by the Pan American Collaborative Retina Study Group showed no improvement in BCVA and central macular thickness. No AEs were also recorded in both studies.
**Golimumab**

Golimumab is a novel human monoclonal TNF-alpha antibody similar to adalimumab which has a systemic half-life of 14 days and molecular weight of 150 kDa. It is usually administered subcutaneously in cases of rheumatoid arthritis, psoriatic arthritis, and HLA-B27-related arthritis and has FDA approval for the same since 2009. Intravitreal administration has not been reported, and only one animal study has been done in which three doses were studied in albino rabbits (5, 10, and 20 mg). Light microscopy showed decreased cell count of outer nuclear layer (ONL) and inner nuclear layer (INL) at all three doses and showed no significant difference in ganglion cell layer (GCL). TUNEL staining showed increased percentage of TUNEL-positive cells in INL (all doses) and ONL (10 and 20 mg). The percentage of TUNEL-positive cells in GCL was not significantly different from that of controls. Caspase-3 staining (irreversible point of programmed cell death) was also significantly different in ONL and INL in all doses of golimumab, while in GCL, it was not. The most prominent ultrastructural change observed on electron microscopy of the golimumab-administered eyes was karyorrhexis in the nucleus and myelin figures in the inner segments of the photoreceptor cells.

**Natalizumab**

Natalizumab is the first selective adhesion molecule inhibitor which has been developed. It attaches to A4B1 integrin and inhibits leukocyte interaction with endothelial receptors, such as VCAM-1 and mucosal addressin cell adhesion molecule-1 and subsequently arresting their translocation and cellular inflammation. It has been approved by FDA for the treatment of multiple sclerosis (MS) and Crohn’s disease. In a study by Chawla et al., on the safety of intravitreal natalizumab in rabbit eyes, three different doses (0.625, 1.25, and 2.5 mg) were injected intravitreally. The low and the intermediate dose did not show any ERG changes from baseline; however, the high dose (2.5 mg) showed reduction of the amplitude of both a- and b-wave. Electron microscopy of the retina of the high-dose group showed alterations in the outer plexiform (deformed synaptic ribbons) and inner nuclear layer (loss of essential organelles, vacuolation in bipolar neurons with damaged and swollen mitochondria).

**Etanercept**

Etanercept is a soluble decoy receptor and binds to TNF1 and TNF2 receptor, thus preventing the binding of TNF-alpha and blocking its proinflammatory effects. It consists of two p75 TNF receptors attached to the Fc portion of human IgG. Etanercept was FDA-approved in 1998 for rheumatoid arthritis, JIA, psoriatic arthritis, and ankylosing spondylitis. Recently, it has been approved for plaque psoriasis in pediatric patients. The systemic half-life of this drug is 4–6 days and molecular weight is 150 kDa.

Animal studies showed no signs of toxicity on clinical evaluation, ERG, and histological examination at doses ranging from 100 μg to 2.5 mg. Peak value of etanercept in the vitreous was noted till 4 weeks after injection, which started declining thereafter. The effect of intravitreal etanercept (0.125 μg) was studied after inducing penetrating ocular injury in rabbit eyes. Fundus examination, USG B-scan, and histopathological examination of etanercept-treated eyes showed reduced formation of PVR changes, such as vitreous haze, epiretinal membrane, retinal folds, and retinal detachment at 30 days compared to controls. RT-PCR showed significant decrease in connective tissue growth factor (CTGF), while TGF-A expression was the same. The study concluded that intravitreal etanercept can be potentially used to prevent PVR formation in retinal detachments. The first and only human trial of intravitreal etanercept was done in patients with diabetic macular edema in which seven eyes were treated with two doses of 2.5 mg/0.1 mL intravitreal etanercept 2 weeks apart. There was no significant change in visual acuity and retinal hemorrhages at the end of 3 months.

**Rituximab**

Rituximab is a chimeric mouse–human monoclonal IgG1 antibody against CD20 antigen which is found on the surface of normal and malignant B lymphocytes. Given that most cases of PVRL or PNCSL are of the CD20-positive DLBCL type, rituximab has shown good results as both systemic and an intravitreal agent. It was first FDA-approved in 1997 as a single intravenous infusion agent in cases of B-cell non-Hodgkin’s lymphoma. The aqueous and vitreous half-life of rituximab (1 mg) is 5.3 and 4.7 days, respectively, and was seen in the vitreous even at 72 days. The aqueous clearance rate of the drug when injected intravitreally is 1.2 mcl/mL which shows that even anterior spread of PIOL can be treated with intravitreal administration. As per a report by Singh and Peereboom, the drug has a low vitreous half-life and needs to be administered more
frequently (two weekly). A single injection of 1 mg/0.1 mL rituximab has been found to penetrate all layers of the retina.\textsuperscript{202}

**Animal studies.** Animal studies have proven the efficacy of intravitreal rituximab in treating eyes with human CD20-transfected murine lymphomatous B cells.\textsuperscript{203} A dose of 1 mg/0.1 mL has shown no evidence of clinical or histological signs of toxicity in rabbits.\textsuperscript{204} Another study evaluated ERG, VEP, histology, and GFAP expression in 12 rabbits with 1 mg rituximab and found no significant changes. However, GFAP was mildly expressed in 6 of the 12 rabbits showing some amount of retinal stress.\textsuperscript{205}

**PVRL (non-Hodgkin’s type).** There are studies that have established the benefit of intravitreal rituximab in PVRL both as a single agent\textsuperscript{206,207} or as a combination therapy with intravitreal MTX.\textsuperscript{208,209} However, alternating doses of MTX and rituximab have been more attractive as it decreases the side effects of MTX.\textsuperscript{15} In a study by Itty \textit{et al.},\textsuperscript{210} a patient who developed recurrence after multiple intravitreal MTX responded on shifting to rituximab, and remission was seen after 10 injections. Following which MTX and rituximab were injected alternatively every week for 3 months and the aqueous biopsy taken after 3 months showed no relapse. However, 6 months later, the patient showed relapse and intravitreal MTX was started again. In a 5-year retrospective study by Giuffrè \textit{et al.},\textsuperscript{211} of 59 eyes of 31 patients of vitreo-retinal lymphoma, 81% were found to develop CNS lymphoma. However, 9 eyes with isolated PVRL underwent intravitreal therapy alone and 32 eyes with concurrent PCNSL underwent a combination of both intravitreal and systemic chemotherapy. MTX and rituximab were injected alternatively every week for 4 weeks followed by two weekly for 3 months. None of the patients developed any complication except for four eyes with IOP rise which was controlled with topical medications. There is a single-case report of a case of choroidal lymphoma showing no response to intravitreal rituximab but achieving complete regression with external beam radiation therapy (EBRT).\textsuperscript{212} In a study by Hashida \textit{et al.},\textsuperscript{213} eyes that developed corneal epitheliopathy with intravitreal MTX were shifted to weekly injections of intravitreal rituximab for 1 month and these were repeated again in case of a recurrence. Clinical improvement was seen in all patients; however, recurrence was seen in 55% of the patients within 3 months and these needed to be treated again. They also showed that the pike-like keratic precipitates and retinal lesions resolved with rituximab which did not resolve with MTX. IOP rise (60%) and anterior uveitis (35%) were the only adverse effects noted in these patients which were controlled with topical medications. In a study by Larkin \textit{et al.},\textsuperscript{214} (48 eyes of which 33 eyes were treatment-naïve) 18 eyes were treated with rituximab alone and the rest were either combined with intravitreal MTX or systemic chemotherapy. Meanwhile, 31 eyes demonstrated complete remission in the study. The complications associated with rituximab were cataract in nine eyes (18.8%); elevated IOP in two eyes (4.2%); granulomatous anterior uveitis in one eye (2.1%); vitreous hemorrhage in one eye (2.1%); and rhegmatogenous retinal detachment in one eye (2.1%). A study by Cicinelli \textit{et al.}\textsuperscript{215} showed reduction of OCT features, such as hyperreflective dots, fuzzy borders, and intraretinal infiltration during remission with rituximab.

**Lymphoma relapse and rituximab.** A patient reported to have bilateral ocular relapse (left eye worse than right) of lymphoma after 10 years of parotid gland DLBCL underwent EBRT in the left eye and 12 monthly intravitreal rituximab injections in the right. The right eye showed complete remission after 12 months and BCVA improved to 20/20.\textsuperscript{216} In another report, a 58-year old lady with relapse of lymphoma underwent weekly intravitreal injections for 4 weeks and subsequently did not show evidence of relapse even after 12 months of the last dose.\textsuperscript{217}

Three monthly doses of intravitreal rituximab following systemic chemotherapy and intravitreal bevacizumab were given to one patient with paraproteinemic maculopathy (serous macular detachment) following an immunoproliferative disorder. However, no significant improvement in visual acuity or reduction of subretinal fluid was noted.\textsuperscript{218} A single case of occlusive vasculopathy has been reported post intravitreal rituximab therapy for intraocular lymphoma.\textsuperscript{219}

**Ublituximab**

Ublituximab (a glycoengineered anti-human CD20 antibody) was injected intracerebrally and intravitreally in murine models of lymphoma-transfected cells at doses of 1, 5, and 20 μg, and a similar dose of 20 μg of rituximab was kept as
control. Doses of 5 and 20 μg showed pronounced effect compared to 1 and 20 μg doses showed better tumor rejection and survival rates compared to those receiving 20 μg of rituximab.220

Conclusion
Intravitreal use of many immunosuppressants and biologics seem to be promising with good safety profile. MTX has been a frontline drug in intraocular lymphoma along with rituximab. The use of intravitreal immunosuppressants and biologics in noninfectious uveitis is gaining popularity in the last decade. As most of these agents do not increase IOP, they may find use in cases where intravitreal steroids cannot be given. Drugs, such as cyclosporine, tacrolimus, golimumab, natalizumab, and etanercept, have shown good safety profile in animal studies. Human studies and clinical trials are needed to look for their safety, tolerability, and efficacy. Many of these agents need to be injected at frequent intervals to achieve long-term benefit. Future development of innovative biodegradable drug delivery systems for these agents would increase their usage. Further studies need to be designed as controlled prospective studies using objective parameters, blinded observers, and measurements performed by an independent operator who is unaware of the treatment received.

Author contribution(s)
Nasiq Hasan: Conceptualization; Formal analysis; Methodology; Writing – original draft; Writing – review & editing.
Rohan Chawla: Project administration; Supervision; Validation.
Nawazish Shaikh: Writing – original draft.
Sindhuja Kandasamy: Writing – original draft.
Shorya Vardhan Azad: Conceptualization; Supervision.
M. Dheepak Sundar: Writing – original draft.

Funding
The authors received no financial support for the research, authorship, and/or publication of this article.

Conflict of interest statement
The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

References
1. Cronstein BN. The mechanism of action of methotrexate. Rheum Dis Clin North Am 1997; 23: 739–755.
2. Bannwarth B, Labat L, Moride Y, et al. Methotrexate in rheumatoid arthritis. An update. Drugs 1994; 47: 25–50.
3. Bedoui Y, Guillot X, Sélambarom J, et al. Methotrexate an old drug with new tricks. Int J Mol Sci 2019; 20: 5023.
4. Ozkan EB, Ozcan AA and Alparslan N. Intravitreal injection of methotrexate in an experimental rabbit model: determination of pharmacokinetics. Indian J Ophthalmol 2011; 59: 197–200.
5. Velez G, Yuan P, Sung C, et al. Pharmacokinetics and toxicity of intravitreal chemotherapy for primary intraocular lymphoma. Arch Ophthalmol 2001; 119: 1518–1524.
6. Ozkan EB, Ozcan AA, Sekeroglu HT, et al. Intravitreal injection of methotrexate in an experimental rabbit model: determination of ultrastructural changes. Indian J Ophthalmol 2013; 61: 329–333.
7. Aly E and Ebrahim A. Apoptosis and electroretinogram after intravitreal injection of methotrexate in an experimental rabbit model. Gen Physiol Biophys 2016; 35: 231–236.
8. Abbaszadeh Hasiri M, Baghaei Moghaddam E, Khalili MR, et al. Intra-vitreal injection of methotrexate in experimental endotoxin-induced uveitis in rabbit. Vet Res Forum 2018; 9: 315–321.
9. Deng SX, Penland S, Gupta S, et al. Methotrexate reduces the complications of endophthalmitis resulting from intravitreal injection compared with dexamethasone in a rabbit model. Invest Ophthalmol Vis Sci 2006; 47: 1516–1521.
10. Eljarrat-Binstock E, Domb AJ, Orocov F, et al. Methotrexate delivery to the eye using transscleral hydrogel iontophoresis. Curr Eye Res 2007; 32: 639–646.
11. Manna S, Augsburger JJ, Correa ZM, et al. Development of chitosan and polylactic acid based methotrexate intravitreal micro-implants to treat primary intraocular lymphoma: an in vitro study. *J Biomech Eng* 2014; 136: 021018.

12. Manna S, Donnell AM, Kaval N, et al. Improved design and characterization of PLGA/PLA-coated Chitosan based micro-implants for controlled release of hydrophilic drugs. *Int J Pharm* 2018; 547: 122–132.

13. Manna S, Augsburger JJ, Correa ZM, et al. Noninvasive electroretinography assessment of intravitreal sustained-release methotrexate microimplants in rabbit eyes. *J Ocul Pharmacol Ther* 2016; 32: 583–594.

14. Palakurthi NK, Correa ZM, Augsburger JJ, et al. Toxicity of a biodegradable microneedle implant loaded with methotrexate as a sustained release device in normal rabbit eye: a pilot study. *J Ocul Pharmacol Ther* 2011; 27: 151–156.

15. Chan C-C, Rubenstein JL, Coupland SE, et al. Primary vitreoretinal lymphoma: a report from an International Primary Central Nervous System Lymphoma Collaborative Group symposium. *Oncologist* 2011; 16: 1589–1599.

16. Karimi M, Soheilian M and Kanavi MR. Bilateral primary intraocular lymphoma. *J Ophthalmic Vis Res* 2011; 6: 344–347.

17. Fishbourne BC, Wilson DJ, Rosenbaum JT, et al. Intravitreal methotrexate as an adjunctive treatment of intraocular lymphoma. *Arch Ophthalmol* 1997; 115: 1152–1156.

18. de Smet MD, Vancs VS, Kohler D, et al. Intravitreal chemotherapy for the treatment of recurrent intraocular lymphoma. *Br J Ophthalmol* 1999; 83: 448–451.

19. Smith JR, Rosenbaum JT, Wilson DJ, et al. Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement. *Ophthalmology* 2002; 109: 1709–1716.

20. Ma W-L, Hou H-A, Hsu Y-J, et al. Clinical outcomes of primary intraocular lymphoma patients treated with front-line systemic high-dose methotrexate and intravitreal methotrexate injection. *Ann Hematol* 2016; 95: 593–601.

21. Frenkel S, Hendler K, Siegal T, et al. Intravitreal methotrexate for treating vitreoretinal lymphoma: 10 years of experience. *Br J Ophthalmol* 2008; 92: 383–388.

22. Sou R, Ohguro N, Maeda T, et al. Treatment of primary intraocular lymphoma with intravitreal methotrexate. *Jpn J Ophthalmol* 2008; 52: 167–174.

23. Wang J-K, Yang C-M, Lin C-P, et al. An Asian patient with intraocular lymphoma treated by intravitreal methotrexate. *Jpn J Ophthalmol* 2006; 50: 474–478.

24. Wang Y, Cheung DS and Chan CC. Case 01-2017 – primary vitreoretinal lymphoma (PVRL): report of a case and update of literature from 1942 to 2016. *Ann Eye Sci* 2017; 2: 32.

25. Kaburaki T, Taoka K, Matsuda J, et al. Combined intravitreal methotrexate and immunochemotherapy followed by reduced-dose whole-brain radiotherapy for newly diagnosed B-cell primary intraocular lymphoma. *Br J Haematol* 2017; 179: 246–255.

26. Castellino A, Pulido JS, Johnston PB, et al. Role of systemic high-dose methotrexate and combined approaches in the management of vitreoretinal lymphoma: a single center experience 1990-2018. *Am J Hematol* 2019; 94: 291–298.

27. Velez G, Boldt HC, Whitcup SM, et al. Local methotrexate and dexamethasone phosphate for the treatment of recurrent primary intraocular lymphoma. *Ophthalmic Surg Lasers* 2002; 33: 329–333.

28. Kamio T, Yokohama A, Hayashi T, et al. [Relapsed primary intraocular lymphoma treated with intravitreal methotrexate and high-dose chemotherapy followed by autologous stem cell rescue]. *Rinsho Ketsueki* 2014; 55: 244–248.

29. Mohammad M, Andrews RM, Plowman PN, et al. Outcomes of intravitreal methotrexate to salvage eyes with relapsed primary intraocular lymphoma. *Br J Ophthalmol* 2022; 106: 135–140.

30. Yeh S and Wilson DJ. Combination intravitreal rituximab and methotrexate for massive subretinal lymphoma. *Eye* 2010; 24: 1625–1627.

31. Jeong Y, Lee EJ and Woo SJ. A case of bilateral iris involvement of lymphoma successfully managed with intravitreal methotrexate injection. *Korean J Ophthalmol* 2020; 34: 498–499.

32. Agarwal A, Sadiq MA, Rhoades WR, et al. Combined systemic and ocular chemotherapy for anterior segment metastasis of systemic mantle cell lymphoma. *J Ophthalmic Inflamm Infect* 2015; 5: 30.

33. Pei M, Zhao C, Gao F, et al. Bilateral mantle cell lymphoma of the ciliary body that responded to a combined local radiotherapy and chemotherapy regimen: a case report. *BMC Cancer* 2019; 19: 355.

34. Singer JR, Nigalye AK, Champion MT, et al. Intravitreal methotrexate for mantle cell...
lymphoma infiltration of the optic nerves: a case report. Retin Cases Brief Rep 2018; 12: 5–9.

35. Gao S, Zhou Y, Jin X, et al. Primary vitreoretinal natural killer/T-cell lymphoma with breast involvement: a case report and review of the literature. Surv Ophthalmol 2019; 64: 225–232.

36. Wickremasinghe SS, Ojaimi E, Lim L, et al. Intravitreal methotrexate as adjuvant, palliative therapy in intraocular T-cell lymphoma. Ocul Immunol Inflamm 2010; 18: 184–186.

37. Reddy R and Kim SJ. Intraocular T-cell lymphoma due to mycosis fungoides and response to intravitreal methotrexate. Ocul Immunol Inflamm 2011; 19: 234–236.

38. Huang JJ. Intraocular metastasis of testicular natural killer T-cell lymphoma with diffuse retinal pigment epithelium changes. Retin Cases Brief Rep 2011; 5: 42–45.

39. Vihnevskia-Dai V, Sella King S, Lekach R, et al. Ocular manifestations of leukemia and results of treatment with intravitreal methotrexate. Sci Rep 2020; 10: 1994.

40. Luiz Guilherme MM, de Paula Effgen P and Kélcia K. Intravitreal methotrexate for iris and ciliary body relapse in acute lymphoblastic leukemia. J Pediatr Ophthalmol Strabismus 2018; 55: e16–e19.

41. Gao J, Panse K, Foster CS, et al. Paraneoplastic acute exudative polymorphous vitelliform maculopathy improved with intravitreal methotrexate. Am J Ophthalmol Case Rep 2020; 20: 100930.

42. Zhao H, Wang X, Mao Y, et al. Longitudinal observation of OCT imaging is a valuable tool to monitor primary vitreoretinal lymphoma treated with intravitreal injections of methotrexate. BMC Ophthalmol 2020; 20: 10.

43. Park YG, Park W-K, Kim R-Y, et al. Serial changes in the aqueous IL-10 level after intravitreal methotrexate injection as an indicator of primary vitreoretinal lymphoma recurrence. Sci Rep 2020; 10: 15992.

44. Raja H, Snyder MR, Johnston PB, et al. Effect of intravitreal methotrexate and rituximab on interleukin-10 levels in aqueous humor of treated eyes with vitreoretinal lymphoma. PLoS ONE 2013; 8: e65627.

45. Kawamura H, Yasuda N, Kakinoki M, et al. Interleukin-10 and interleukin-6 in aqueous humor during treatment of vitreoretinal lymphoma with intravitreally injected methotrexate. Ophthalmic Res 2009; 42: 172–174.

46. Choi S, Shin S, Lee S-T, et al. Serial detection of MYD88 L265P mutation in the aqueous humor of a patient with vitreoretinal lymphoma for disease monitoring. Ocul Immunol Inflamm 2021; 29: 485–489.

47. Hardwig PW, Pulido JS, Eric JC, et al. Intraocular methotrexate in ocular diseases other than primary central nervous system lymphoma. Am J Ophthalmol 2006; 142: 883–885.

48. Taylor SRJ, Habot-Wilner Z, Pacheco P, et al. Intraocular methotrexate in the treatment of uveitis and uveitic cystoid macular edema. Ophthalmology 2009; 116: 797–801.

49. Taylor SRJ, Banker A, Schlaen A, et al. Intraocular methotrexate can induce extended remission in some patients in noninfectious uveitis. Retina 2013; 33: 2149–2154.

50. JHSPH Center for Clinical Trials. Macular edema ranibizumab v. intravitreal anti-inflammatory therapy trial. Report No. NCT02623426, clinicaltrials.gov, https://clinicaltrials.gov/ct2/show/NCT02623426 (2020, accessed 28 April 2021).

51. Chin EK, Almeida DRP and Mahajan VB. Management of choroidal granulomas involving the macula in corticosteroid-intolerant patients. JAMA Ophthalmol 2015; 133: 1351–1352.

52. Arora A, Katoch D, Jain S, et al. Yellow subretinal lesions following initiation of antituberculosis therapy in a tubercular choroidal granuloma: a sign of paradoxical worsening? Ocul Immunol Inflamm 2022; 30: 29–33.

53. Tsui E, Fern CM and Goldberg NR. Treatment of refractory tubercular serpiginous-like choroiditis with intravitreal methotrexate. Retin Cases Brief Rep 2021; 15: 169–173.

54. Julian K, Langner-Wegscheider B-J, Haas A, et al. Intravitreal methotrexate in the management of presumed tuberculous serpiginous-like choroiditis. Retina 2013; 33: 1943–1948.

55. Sahin O and Ziaei A. The role of methotrexate in resolving ocular inflammation after specific therapy for presumed latent syphilitic uveitis and presumed tuberculosis-related uveitis. Retina 2014; 34: 1451–1459.

56. Bae JH and Lee SC. Effect of intravitreal methotrexate and aqueous humor cytokine levels in refractory retinal vasculitis in Behcet disease. Retina 2012; 32: 1395–1402.

57. Khalil HEDM, El Gendy HA, Youssef HAR, et al. The effectiveness of intraocular methotrexate in the treatment of posterior uveitis in Behçet’s disease patients compared to
Therapeutic Advances in Ophthalmology 14

56. Aldeyra Therapeutics, Inc. The GUARD trial – part 1: a phase 3 clinical trial of repeated intravitreal injections of ADX-2191 versus standard-of-care for prevention of proliferative vitreoretinopathy. Report No. NCT04136366, clinicaltrials.gov, https://clinicaltrials.gov/ct2/show/NCT04136366 (2021, accessed 28 April 2021).

57. Kurup SK, Gee C and Greven CM. Intravitreal methotrexate in therapeutically resistant exudative age-related macular degeneration. Acta Ophthalmol 2010; 88: e145–e146.

58. Jeong Y, Ryu JS, Park UC, et al. Corneal epithelial toxicity after intravitreal methotrexate injection for vitreoretinal lymphoma: clinical and in vitro studies. J Clin Med 2020; 9: 2672.

59. Zhou X, Zhou X, Shi H, et al. Reduced frequency of intravitreal methotrexate injection lowers the risk of keratopathy in vitreoretinal lymphoma patients. BMC Ophthalmol 2020; 20: 189.

60. Gorovoy I, Prechanond T, Abia M, et al. Toxic corneal epitheliopathy after intravitreal methotrexate and its treatment with oral folic acid. Cornea 2013; 32: 1171–1173.

61. Sahay P, Maharana PK, Temkar S, et al. Corneal epithelial toxicity with intravitreal methotrexate in a case of B-cell lymphoma with ocular involvement. BMJ Case Rep 2018; 2018: bcr2018226005.

62. Ghasemi Falavarjani K, Golabi S and Hadavandkhani A. Effect of intravitreal injection of methotrexate on human corneal endothelial cells. Cornea 2016; 35: 217–219.

63. Sen HN, Chan C-C, Byrnes G, et al. Intravitreal methotrexate resistance in a patient with primary intraocular lymphoma. Ocul Immunol Inflamm 2008; 16: 29–33.

64. Venkatesh P, Gogia V, Khanduja S, et al. Therapeutic vitrectomy for vitreal recurrence of retrobulbar steroids injection. J Ophthalmol 2016; 2016: 1678495.
intraocular lymphoma resistant to intravitreal methotrexate post systemic chemotherapy. J Cancer Res Ther 2015; 11: 668.

82. Sehgal SN. Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc 2003; 35(Suppl. 3): 7S–14S.

83. Thomson AW, Turnquist HR and Raimondi G. Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol 2009; 9: 324–337.

84. Paghdal KV and Schwartz RA. Sirolimus: from the soil of Easter Island to a bright future. J Am Acad Dermatol 2007; 57: 1046–1050.

85. Sen HN, Larson TA, Meleth AD, et al. Subconjunctival sirolimus for the treatment of chronic active anterior uveitis: results of a pilot trial. Am J Ophthalmol 2012; 153: 1038–1042.

86. Douglas LC, Yi NY, Davis JL, et al. Ocular toxicity and distribution of subconjunctival and intravitreal rapamycin in horses. J Vet Pharmacol Ther 2008; 31: 511–516.

87. Manzano RPdA, Peyman GA, Khan P, et al. Testing intravitreal toxicity of rapamycin in rabbit eyes. Arq Bras Oftalmol 2009; 72: 18–22.

88. Ichikawa A, Nakahara T, Kurauchi Y, et al. Rapamycin prevents N-methyl-D-aspartate-induced retinal damage through an ERK-dependent mechanism in rats. J Neurosci Res 2014; 92: 692–702.

89. Aoki Y, Nakahara T, Asano D, et al. Preventive effects of rapamycin on inflammation and capillary degeneration in a rat model of NMDA-induced retinal injury. Biol Pharm Bull 2015; 38: 321–324.

90. De Paiva MRB, Lage NA, Guerra MCA, et al. Toxicity and in vivo release profile of sirolimus from implants into the vitreous of rabbits’ eyes. Doc Ophthalmol 2019; 138(Suppl. 3): 7S–14S.

91. Abud MB, Louzada RN, Isaac DLC, et al. In vivo and in vitro toxicity evaluation of liposome-encapsulated sirolimus. Int J Retina Vitreous 2019; 5: 35.

92. Wu W, He Z, Zhang Z, et al. Intravitreal injection of rapamycin-loaded polymeric micelles for inhibition of ocular inflammation in rat model. Int J Pharm 2016; 513: 238–246.

93. Hou H, Nieto A, Belghith A, et al. A sustained intravitreal drug delivery system with remote real time monitoring capability. Acta Biomater 2015; 24: 309–321.

94. Nieto A, Hou H, Moon SW, et al. Surface engineering of porous silicon microparticles for intravitreal sustained delivery of rapamycin. Invest Ophthalmol Vis Sci 2015; 56: 1070–1080.

95. Nguyen QD, Ibrahim MA, Watters A, et al. Ocular tolerability and efficacy of intravitreal and subconjunctival injections of sirolimus in patients with non-infectious uveitis: primary 6-month results of the SAVE study. J Ophthalmic Inflamm Infect 2013; 3: 32.

96. Ibrahim MA, Sepah YJ, Watters A, et al. One-year outcomes of the SAVE study: sirolimus as a therapeutic approach for UVetis. Transl Vis Sci Technol 2015; 4: 4, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4356037/ (accessed 15 April 2021).

97. Vigil EM, Sepah YJ, Watters AL, et al. Assessment of changes in quality of life among patients in the SAVE study – sirolimus as therapeutic approach to uVEitis: a randomized study to assess the safety and bioactivity of intravitreal and subconjunctival injections of sirolimus in patients with non-infectious uveitis. J Ophthalmic Inflamm Infect 2015; 5: 13.

98. Nguyen QD, Sadiq MA, Soliman MK, et al. The effect of different dosing schedules of intravitreal sirolimus, a mammalian target of rapamycin (mTOR) inhibitor, in the treatment of non-infectious uveitis (An American Ophthalmological Society Thesis). Trans Am Ophthalmol Soc 2016; 114: T3.

99. Nguyen QD, Merrill PT, Clark WL, et al. Intravitreal sirolimus for noninfectious uveitis: a phase III Sirolimus Study Assessing Double-Masked Uveitis Treatment (SAKURA). Ophthalmology 2016; 123: 2413–2423.

100. Lescauwraet B, Miserocchi E, Thurau S, et al. Association between visual function response and reduction of inflammation in noninfectious uveitis of the posterior segment. Invest Ophthalmol Vis Sci 2017; 58: 3555–3562.

101. Merrill PT, Clark WL, Banker AS, et al. Efficacy and safety of intravitreal sirolimus for noninfectious uveitis of the posterior segment: results from the Sirolimus Study Assessing Double-Masked Uveitis Treatment (SAKURA) Program. Ophthalmology 2020; 127: 1405–1415.

102. Petrou PA, Cunningham D, Shimel K, et al. Intravitreal sirolimus for the treatment of geographic atrophy: results of a phase I/II clinical trial. Invest Ophthalmol Vis Sci 2014; 56: 330–338.

103. Gensler G, Clemens TE, Domalpally A, et al. Treatment of geographic atrophy with intravitreal sirolimus: the Age-Related Eye Disease Study 2 ancillary study. Ophthalmol Retina 2018; 2: 441–450.

104. Minturn RJ, Bracha P, Klein MJ, et al. Intravitreal sirolimus for persistent, exudative...
age-related macular degeneration: a pilot study. 

105. Bracha P, Chhablani J, Harless A, et al. Prospective, randomized, subject-masked evaluation of intravitreal Sirolimus vs. anti-VEGF in chronic neovascular AMD with persistent retinal fluid: 1-year follow-up. 

106. Sirolimus/afibercept combo shows potential benefits for wet AMD. 

107. Dugel PU, Blumenkranz MS, Haller JA, et al. A randomized, dose-escalation study of subconjunctival and intravitreal injections of sirolimus in patients with diabetic macular edema. 

108. Russell G, Graveley R, Seid J, et al. Mechanisms of action of cyclosporine and effects on connective tissues. 

109. Drug approval package: restasis NDA #021023, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-023_Restasis.cfm (accessed 18 April 2021). 

110. Liversidge J, Sewell HF, Thomson AW, et al. Lymphokine-induced MHC class II antigen expression on cultured retinal pigment epithelial cells and the influence of cyclosporin A. 

111. Jaffe GJ, Yang CS, Wang XC, et al. Intravitreal sustained-release cyclosporine in the treatment of experimental uveitis. 

112. Wang P, Chen F and Zhang X. Cyclosporine-a attenuates retinal inflammation by inhibiting HMGB-1 formation in rats with type 2 diabetes mellitus. 

113. Zong YJ, Shen Q, Zhang XD, et al. The protective effects on the function and structure of retinae in diabetic rats by intravitreal injection of cyclosporin A. 

114. Karaküçük S, Soyuer S, Oner AO, et al. Experimental posterior perforating ocular injury in rabbit eyes: effects of radiotherapy with or without intravitreal cyclosporin on vitreous proliferation. 

115. Oh JO, Minasi P, Grabner G, et al. Suppression of secondary herpes simplex uveitis by cyclosporine. 

116. Grisolano J and Peyman GA. Retinal toxicity study of intravitreal cyclosporin. 

117. del Cerro M, Seigel GM, Lazar E, et al. Transplantation of Y79 cells into rat eyes: an in vivo model of human retinoblastomas. 

118. Lai CC, Gouras P, Doi K, et al. Local immunosuppression prolongs survival of RPE xenografts labeled by retroviral gene transfer. 

119. Alghadyan AA, Peyman GA, Khoobehi B, et al. Liposome-bound cyclosporine: clearance after intravitreal injection. 

120. Ashton P, Blandford DL, Pearson PA, et al. Review: implants. 

121. Pearson PA, Jaffe GJ, Martin DF, et al. Evaluation of a delivery system providing long-term release of cyclosporine. 

122. Enyedi LB, Pearson PA, Ashton P, et al. An intravitreal device providing sustained release of cyclosporine and dexamethasone. 

123. Dong X, Shi W, Yuan G, et al. Intravitreal implantation of the biodegradable cyclosporin A drug delivery system for experimental chronic uveitis. 

124. He Y, Wang J-C, Liu Y-L, et al. Therapeutic and toxicological evaluations of cyclosporine a microspheres as a treatment vehicle for uveitis in rabbits. 

125. Gilger BC, Malok E, Stewart T, et al. Long-term effect on the equine eye of an intravitreal device used for sustained release of cyclosporine A. 

126. Gilger BC, Malok E, Stewart T, et al. Effect of an intravitreal cyclosporine implant on experimental uveitis in horses. 

127. Gilger BC, Wilkie DA, Davidson MG, et al. Use of an intravitreal sustained-release cyclosporine delivery device for treatment of equine recurrent uveitis. 

128. McMullen RJ Jr and Fischer BM. Medical and surgical management of equine recurrent uveitis. 

494–500. 

1985; 26: 

2006; 220: 6–11. 

1988; 63: 313–317. 

1992; 114: 311–317. 

1996; 114: 311–317. 

2000; 76: 239–255. 

2000; 3: 105–110. 

2003; 7: 11. 

2017; 33: 

2012; 48: 591–597. 

2012; 58: 2967–2967. 

2018; 12: 109–112. 

2001; 62: 1892–1896. 

2000; 15: 549–557. 

2006; 12: 691–701. 

2003/21-023_Restasis.cfm (accessed 18 April 2021). 

2006; 22: 

1998; 12: 124–131. 

1992; 21(6 Suppl. 3): 16–22. 

2017; 33: 465–481. 

2006; 26: 

1993; 34: 3336–3346. 

1986; 17: 155–156. 

1996; 15: 549–557. 

2006; 244: 492–497, https://pubmed.ncbi.nlm.nih.gov/16163496/ (accessed 14 February 2021). 

1988; 12: 

1986; 17: 155–156. 

1993; 10: 

1994; 10: 109–112. 

1996; 11: 549–557. 

2006; 22: 121–131. 

2000; 2: 159–168. 

2000; 2: 169–175. 

2006; 1: 69–80. 

2006; 11: 311–317. 

2006; 7: 11. 

2017; 33: 465–481.
129. Oh-i K, Keino H, Goto H, et al. Intravitreal injection of tacrolimus (FK506) suppresses ongoing experimental autoimmune uveoretinitis in rats. Br J Ophthalmol 2007; 91: 237–242.

130. Ishikawa T, Hokama H, Katagiri Y, et al. Effects of intravitreal injection of tacrolimus (FK506) in experimental uveitis. Curr Eye Res 2005; 30: 93–101.

131. Araya AA and Tasnif Y. Tacroolimus. Treasure Island, FL: StatPearls Publishing, 2021, http://www.ncbi.nlm.nih.gov/books/NBK544318/ (accessed 14 April 2021).

132. Passos E, Genaidy MM and Peyman GA. Ocular toxicity of intravitreal tacrolimus. Ophthalmic Surg Lasers 2002; 33: 140–144.

133. Li S, Tang S, Li W, et al. Experiment study of retinal ultrastructure after intravitreal FK506. Yan Ke Xue Bao 2004; 20: 34–38.

134. Rosenstiel P, Schramm P, Isenmann S, et al. Differential effects of immunophilin-ligands (FK506 and V-10,367) on survival and regeneration of rat retinal ganglion cells in vitro and after optic nerve crush in vivo. J Neurotrauma 2003; 20: 297–307.

135. Park CH, Kim YS, Kim YH, et al. Calcineurin mediates AKT dephosphorylation in the ischemic rat retina. Brain Res 2008; 1234: 148–157.

136. Oh-i K, Keino H, Goto H, et al. Upregulation of neurotrophic factor-related gene expression in retina with experimental autoimmune uveoretinitis by intravitreal injection of tacrolimus (FK506). Br J Ophthalmol 2007; 91: 1537–1540.

137. Turgut B, Uyar F, Ustundag B, et al. The impact of tacrolimus on growth factors in experimental proliferative vitreoretinopathy. Retina 2012; 32: 232–241.

138. Scleral plug of biodegradable polymers containing tacrolimus (FK506) for experimental uveitis| IOVS| ARVO Journals, https://iovs.arvojournals.org/article.aspx?articleid=2181691 (accessed 13 April 2021).

139. Zhang R, He R, Qian J, et al. Treatment of experimental autoimmune uveoretinitis with intravitreal injection of tacrolimus (FK506) encapsulated in liposomes. Invest Ophthalmol Vis Sci 2010; 51: 3575–3582.

140. Paiva MRB, Andrade GF, Dourado LFN, et al. Surface functionalized mesoporous silica nanoparticles for intravitreal application of tacrolimus. J Biomater Appl 2021; 35: 1019–1033.

141. Souza MCM, Fialho SL, Souza PA, et al. Tacrolimus-loaded PLGA implants: in vivo release and ocular toxicity. Curr Eye Res 2014; 39: 99–102.

142. Markham A and Lamb HM. Infliximab: a review of its use in the management of rheumatoid arthritis. Drugs 2000; 59: 1341–1359.

143. Rutgeerts P, Vermeire S and Van Assche G. Biological therapies for inflammatory bowel diseases. Gastroenterology 2009; 136: 1182–1197.

144. Robinson DM and Keating GM. Infliximab: in ankylosing spondylitis. Drugs 2005; 65: 1283–1291; discussion 1292–1294.

145. Theodossiadis PG, Liarakos VS, Sfikakis PP, et al. Intravitreal administration of the anti-tumor necrosis factor agent infliximab for neovascular age-related macular degeneration. Am J Ophthalmol 2009; 147: 825–830, 830.e1.

146. Remicade (infliximab) FDA approval history. Drugs.com, https://www.drugs.com/history/remicade.html (accessed 23 April 2021).

147. Monaco C, Nanchahal J, Taylor P, et al. Anti-TNF therapy: past, present and future. Int Immunol 2015; 27: 55–62.

148. Giansanti F, Ramazzotti M, Giuntoli M, et al. Intravitreal infliximab clearance in a rabbit model: different sampling methods and assay techniques. Invest Ophthalmol Vis Sci 2009; 50: 5328–5335.

149. Giansanti F, Ramazzotti M, Vannozzi L, et al. A pilot study on ocular safety of intravitreal infliximab in a rabbit model. Invest Ophthalmol Vis Sci 2008; 49: 1151–1156.

150. Zayit-Soudry S, Vainer I, Zemel E, et al. Infliximab exerts a dose-dependent effect on retinal safety in the albino rabbit. Doc Ophthalmol 2017; 135: 175–185.

151. Theodossiadis PG, Liarakos VS, Sfikakis PP, et al. Intravitreal infliximab clearance in a rabbit model: different sampling methods and assay techniques. Invest Ophthalmol Vis Sci 2009; 50: 5328–5335.

152. Sekhar K, Chawla R. Ocular toxicity of intravitreal tacrolimus. Exp Eye Res 2009; 89: 399–406.

153. Giansanti F, Ramazzotti M, Giuntoli M, et al. Intravitreal infliximab clearance in a rabbit model: different sampling methods and assay techniques. Invest Ophthalmol Vis Sci 2009; 50: 5328–5335.

154. Sekhar K, Chawla R. Ocular toxicity of intravitreal tacrolimus. Exp Eye Res 2009; 89: 399–406.
intravitreal injections of infliximab in rabbits eyes. Arq Bras Oftalmol 2011; 74: 352–356.

155. Beer PM, Wong SJ, Schartman JP, et al. Infliximab stability after reconstitution, dilution, and storage under refrigeration. Retina 2010; 30: 81–84.

156. Hosseini H, Safaei A, Khalili MR, et al. Intravitreal infliximab in experimental endotoxin-induced uveitis. Eur J Ophthalmol 2009; 19: 818–823.

157. Zhang R, Qian J, Li X, et al. Treatment of experimental autoimmune uveoretinitis with intravitreal injection of infliximab encapsulated in liposomes. Br J Ophthalmol 2017; 101: 1731–1738.

158. Ondas O, Ates O, Keles S, et al. Intravitreal infliximab injection to treat experimental endophthalmitis. Eurasian J Med 2017; 49: 167–171.

159. Yuksel E, Hasanreisoglu B, Yuksel N, et al. Comparison of acute effect of systemic versus intravitreal infliximab treatment in an experimental model of endotoxin-induced uveitis. J Ocul Pharmacol Ther 2014; 30: 74–80.

160. Donmez O, Yaman A, Ozturk T, et al. The efficacy of systemic and intravitreal infliximab treatments in an endotoxin-induced uveitis model. Cutan Ocul Toxicol 2019; 38: 360–369.

161. Olson JL, Courtney RJ and Mandava N. Intravitreal infliximab and choroidal neovascularization in an animal model. Arch Ophthalmol 2007; 125: 1221–1224.

162. Regatieri CV, Dreyfuss JL, Melo GB, et al. Dual role of intravitreous infliximab in experimental choroidal neovascularization: effect on the expression of sulfated glycosaminoglycans. Invest Ophthalmol Vis Sci 2009; 50: 5487–5494.

163. Savur F, Aydemir O and Illhan N. The effect of infliximab and octreotide on cytokine levels experimental proliferative vitreoretinopathy. Cutan Ocul Toxicol 2020; 39: 61–66.

164. Farvardin M, Afarid M, Mehryar M, et al. Intravitreal infliximab for the treatment of sight-threatening chronic noninfectious uveitis. Retina 2010; 30: 1530–1535.

165. Farvardin M, Afarid M and Shahrzad S. Long-term effects of intravitreal infliximab for treatment of sight-threatening chronic noninfectious uveitis. J Ocul Pharmacol Ther 2012; 28: 628–631.

166. Hamza MME, Macky TA, Sidky MK, et al. Intravitreal infliximab in refractory uveitis in Behçet’s disease: a safety and efficacy clinical study. Retina 2016; 36: 2399–2408.

167. Markomichehakis N, Delicha E, Masselos S, et al. Intravitreal infliximab for sight-threatening relapsing uveitis in Behcet disease: a pilot study in 15 patients. Am J Ophthalmol 2012; 154: 534–541.e1.

168. Wu L, Arevalo JF, Hernandez-Bogantes E, et al. Intravitreal infliximab for refractory pseudophakic cystoid macular edema: results of the Pan-American Collaborative Retina Study Group. Int Ophthalmol 2012; 32: 235–243.

169. Arias L, Caminal JM, Badia MB, et al. Intravitreal infliximab in patients with macular degeneration who are nonresponders to antivascular endothelial growth factor therapy. Retina 2010; 30: 1601–1608.

170. Semeraro F, Romano MR, Danzi P, et al. Intravitreal infliximab for choroidal neovascularization in patients refractory to conventional treatments. Int J Immunopathol Pharmacol 2013; 26: 765–768.

171. de Freitas LGA, Isaac DLC, Tannure WT, et al. Intravitreal bevacizumab combined with infliximab in the treatment of choroidal neovascularization secondary to age-related macular degeneration: case report series. Arq Bras Oftalmol 2013; 76: 180–184.

172. Wu L, Hernandez-Bogantes E, Roca JA, et al. Intravitreal tumor necrosis factor inhibitors in the treatment of refractory diabetic macular edema: a pilot study from the Pan–American Collaborative Retina Study Group. Retina 2011; 31: 298–303.

173. Giganti M, Beer PM, Lemanski N, et al. Adverse events after intravitreal infliximab (Remicade). Retina 2010; 30: 71–80.

174. Vena GA and Cassano N. Drug focus: adalimumab in the treatment of moderate to severe psoriasis. Biologics 2007; 117: 1612–1616.

175. Humira (adalimumab) FDA approval history. Drugs.com, https://www.drugs.com/history/humira.html (accessed 23 April 2021).

176. Androudi S, Tsironi E, Kalogeropoulos C, et al. Intravitreal adalimumab for refractory uveitis-related macular edema. Ophthalmology 2010; 117: 1612–1616.

177. Manzano RPA, Peyman GA, Carvounis PE, et al. Ocular toxicity of intravitreous adalimumab (Humira) in the rabbit. Graefes Arch Clin Exp Ophthalmol 2008; 246: 907–911.

178. Manzano RPA, Peyman GA, Carvounis PE, et al. Toxicity of high-dose intravitreal
179. Tsilimbaris M, Diakonis VF, Naoumidi I, et al. Evaluation of potential retinal toxicity of adalimumab (Humira). *Graefes Arch Clin Exp Ophthalmol* 2009; 247: 1119–1125.

180. Myers AC, Ghosh F, Andrésansson S, et al. Retinal function and morphology in the rabbit eye after intravitreal injection of the TNF alpha inhibitor adalimumab. *Curr Eye Res* 2014; 39: 1106–1116.

181. de Paula ACC, de Ávila MP, Isaac DLC, et al. Cytotoxicity and genotoxicity of intravitreal adalimumab administration in rabbit retinal cells. *Arq Bras Oftalmol* 2015; 78: 89–93.

182. Olivares-González L, Velasco S,Millán JM, et al. Intravitreal administration of adalimumab delays retinal degeneration in rd10 mice. *FASEB J* 2020; 34: 13839–13861.

183. Lichtent P, Lam TT, Nork TM, et al. Relative contribution of VEGF and TNF-alpha in the cynomolgus laser-induced CNV model: comparing the efficacy of bevacizumab, adalimumab, and ESBA105. *Invest Ophthalmol Vis Sci* 2010; 51: 4738–4745.

184. Hamam RN, Barikian AW, Antonios RS, et al. Intravitreal adalimumab in active noninfectious uveitis: a pilot study. *Ocul Immunol Inflamm* 2016; 24: 319–326.

185. Kheir WJ, Mehanna CJ, Abdul Fattah M, et al. Intravitreal adalimumab for the control of breakthrough intraocular inflammation. *Ocul Immunol Inflamm* 2018; 26: 1206–1211.

186. Farvardin M, Namvar E, Sanie-Jahromi F, et al. The effects of intravitreal adalimumab injection on pseudophakic macular edema. *BMC Res Notes* 2020; 13: 354.

187. Arevalo JF, Serrano MA and Wu L. Combined inhibition of tumor necrosis factor (TNF) and vascular endothelial growth factor (VEGF) for the treatment of macular edema of various etiologies: a short-term pilot study. *Eye* 2013; 27: 569–571.

188. Wu L, Arevalo JF, Hernandez-Bogantes E, et al. Intravitreal tumor necrosis factor-alpha inhibitors for neovascular age-related macular degeneration suboptimally responsive to antivascular endothelial growth factor agents: a pilot study from the Pan American Collaborative Retina Study Group. *J Ocul Pharmacol Ther* 2013; 29: 366–371.

189. Keystone EC, Genovese MC, Klareskog L, et al. Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. *Ann Rheum Dis* 2009; 68: 789–796.

190. Durmaz Engin C, Cilaker Miçili S, Yilmaz O, et al. Ocular toxicity of intravitreal golimumab in a rabbit model. *Turk J Med Sci* 2020; 50: 1111–1122.

191. Polman CH, O’Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. *N Engl J Med* 2006; 354: 899–910.

192. Kawamoto E, Nakahashi S, Okamoto T, et al. Anti-integrin therapy for multiple sclerosis. *Autoimmune Dis* 2012; 2012: 357101.

193. Ghosh S, Goldin E, Gordon FH, et al. Natalizumab for active Crohn’s disease. *N Engl J Med* 2003; 348: 24–32.

194. Chawla R, Nath M, Molsha L, et al. An experimental study to evaluate safety/toxicity of intravitreal natalizumab. *Indian J Ophthalmol* 2018; 66: 1441–1445.

195. Peppel K, Crawford D and Beutler B. A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity. *J Exp Med* 1991; 174: 1483–1489.

196. Kivilcim M, Peyman GA, Kazi AA, et al. Intravitreal toxicity of high-dose etanercept. *J Ocul Pharmacol Ther* 2007; 23: 57–62.

197. Fauser S, Kalbacher H, Alteheld N, et al. Pharmacokinetics and safety of intravitreally delivered etanercept. *Graefes Arch Clin Exp Ophthalmol* 2004; 242: 582–586.

198. Chen X-F, Du M, Wang XH, et al. Effect of etanercept on post-traumatic proliferative vitreoretinopathy. *Int J Ophthalmol* 2006; 29: 731–738.

199. Polman CH, O’Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. *N Engl J Med* 2006; 354: 899–910.

200. Kim H, Csaky KG, Chan CC, et al. The pharmacokinetics of rituximab following an intravitreal injection. *Exp Eye Res* 2006; 82: 760–766.

201. Singh AD and Peereboom DM. Intraocular toxicity of intravitreal etanercept. *Semin Ophthalmol* 2007; 22: 75–79.

202. Pulido JS, Bakri SJ, Valyi-Nagy T, et al. Rituximab penetrates full-thickness retina in contrast to tissue plasminogen activator control. *Retina* 2007; 27: 1071–1073.
203. Mineo J-F, Scheffer A, Karkoutly C, et al. Using human CD20-transfected murine lymphomatous B cells to evaluate the efficacy of intravitreal and intracerebral rituximab injections in mice. *Invest Ophthalmol Vis Sci* 2008; 49: 4738–4745.

204. Kitzmann AS, Pulido JS, Mohney BG, et al. Intraocular use of rituximab. *Eye* 2007; 21: 1524–1527.

205. Habot-Wilner Z, Shahar J, Zemel E, et al. Retinal toxicity of intravitreal rituximab in albino rabbits. *Retina* 2013; 33: 649–656.

206. Kitzmann AS, Pulido JS, Garrity JA, et al. Histologic findings in T-cell lymphoma infiltration of the optic nerve. *Ophthalmology* 2008; 115: e1–e6.

207. Ohguro N, Hashida N and Tano Y. Effect of intravitreous rituximab injections in patients with recurrent ocular lesions associated with central nervous system lymphoma. *Arch Ophthalmol* 2008; 126: 1002–1003.

208. Itty S and Pulido JS. Rituximab for intraocular lymphoma. *Retina* 2009; 29: 129–132.

209. Abu Samra K, Oray M, Ebrahimiadib N, et al. Intraocular lymphoma: descriptive data of 26 patients including clinico-pathologic features, vitreous findings, and treatment outcomes. *Ocul Immunol Inflamm* 2018; 26: 347–352.

210. Itty S, Olson JH, O’Connell DJ, et al. Treatment of primary intraocular lymphoma (PIOL) has involved systemic, intravitreal or intrathecal chemotherapy and/or radiotherapy. *Retina* 2009; 29: 415–416.

211. Giuffrè C, Cicinelli MV, Marchese A, et al. Clinical experience in a large cohort of patients with vitreoretinal lymphoma in a single center. *Ocul Immunol Inflamm* 2021; 29: 472–478.

212. Hernández-Pons A, Gómez-Beltrán E, Fernández-Zarzoso M, et al. Choroidal lymphoma diagnosed by polymerase chain reaction-based clonality assessment. *Eur J Ophthalmol* 2021; 31: NP97–NP101.

213. Hashida N, Ohguro N and Nishida K. Efficacy and complications of intravitreal rituximab injection for treating primary vitreoretinal lymphoma. *Transl Vis Sci Technol* 2012; 1: 1.

214. Larkin KL, Saboo US, Comer GM, et al. Use of intravitreal rituximab for treatment of vitreoretinal lymphoma. *Br J Ophthalmol* 2014; 98: 99–103.

215. Cicinelli MV, Marchese A, Miserochli E, et al. Retinal and choroidal changes of vitreoretinal lymphoma from active to remission phase after intravitreal rituximab. *Ocul Immunol Inflamm* 2020; 28: 637–646.

216. Echegaray JJ, Llop S, Sepulveda M, et al. Intravitreal rituximab for the treatment of a secondary intraocular relapse of a large B-cell lymphoma. *Am J Ophthalmol Case Rep* 2018; 9: 77–79.

217. Fernández-Cañabate E and Fernández-Cañabate S. [Intravitreal rituximab for the treatment of intraocular relapse of non-Hodgkin’s lymphoma]. *Farm Hosp* 2018; 42: 20–21.

218. Mansour AM, Arevalo JF, Badal J, et al. Paraproteinemic maculopathy. *Ophthalmology* 2014; 121: 1925–1932.

219. Conrady CD and Shakoor A. Rituximab-associated retinal occlusive vasculopathy: a case report and literature review. *Ocul Immunol Inflamm* 2020; 28: 622–625.

220. Ben Abdelwahed R, Donnou S, Ouakrim H, et al. Preclinical study of ublituximab, a glycoengineered anti-human CD20 antibody, in murine models of primary cerebral and intraocular B-cell lymphomas. *Invest Ophthalmol Vis Sci* 2013; 54: 3657–3665.